index [jpet.aspetjournals.org] · 2006. 1. 7. · 1306 index vol.276 and beta adrenergic receptor...
TRANSCRIPT
1304
INDEX
Volume 276, January-March, 1996
A-77636, studies, receptor desensitization,
dopamine D1 receptor effects,1022
A-127722, pharmacological characteriza-tion, 473
An, E. M. van der, Wouterse, A. C., Verrijt,C. E. H., Peereboom-Stegeman, J.H. J. C. and Russel, F. G. M.: Up-take of cimetidine into syncytialmicrovillus membrane vesicles of
human term placenta, 219Abboa-Offei, B. E., see Seymour, A. A., 708
Abbruscato, T. J., Williams, S. A., Isicka,A. M., Lipkowski, A. W., Hruby,V. J. and Davis, T. P.: Blood-to-central nervous system entry andstability of (Try-D-Ala-Gly-Phe-NH)2 a unique double-enkepha-lin analog, and its halogenatedderivatives, 1049
Abe, Y., Ishisu, R., Onishi, K., Sekioka, K.,
Narimatsu, A. and Nakano, T.:Calcium sensitization in perfusedbeating guinea pig heart by a pos-itive inotropic agent MCI-154,433
Abi-Younes, S., see Farhat, M. Y., 652ABT-431, in vitro characterization and ef-
fects in animal models of Parkin-
son’s disease, 150
Acetylcholinechloride current oscillations, in swine
tracheal smooth muscle cells, 178release, gastric motility and, TKS159 ef-
fects, guinea pig stomach, 989Acetylcholine receptors
nicotinica4�2, expression, pharmacologic prop-
erties and regulation, 289agonist epibatidine, effects on neuro-
transmitter release, in rats, 509neural effects in medial septum, 482reduction by nereistoxin, whole chick
ciliary ganglion studies, 169
presynaptic control of dopamine release
by, in rat striatum synaptosomes,616
Acidification, urine, enhancement of or-ganic cation secretion by, 683
Acrylamide neuropathy, 4-methylcatechol
effects on recovery from, 231
Adenosine receptorsA1, antagonist WRC-0571, characteriza-
tion, 490A2a antagonist SCH 58261, pharmaco-
logical profile, 398A3, phospholipase D activation via, in
rat mast cells, 837‘25I�pE binding, in coronary artery,
284Adenosine triphosphate, renal cellular, de-
pletion by iodoacetate and cya-
nide, in distal tubular cells, 194Adkison, K. D. K. and Shen, D. D.: Uptake
of valproic acid into rat brain is
mediated by a medium-chainfatty acid transporter, 1189
Adler, A. L., see Opgenorth, T. J., 473
Adrenal chromaffin cells, ascorbic acidtransport into, palytoxin effects,
996Adrenoceptors
alpha, myocardial, ontogenic differencesin functions of, 1155
betaand inositol phosphate generation, in
pregnant rat myometrium, 130
renin secretory response to, phos-phodiesterase IV inhibitor rolip-ram and, 1073
stimulation, canine stomach, hista-mine release and, 984
Agmatine, imidazoline receptors and, in
blood vessels, 1272Agnati, L. F., see De Gennaro Colonna, V.,
795Alaoui-Jamali, M., see Wang, T., 1169Albumin, bupivacaine binding, human,
109Alcohol, see also Ethanol
tolerance, single exposure to combinedethanol and arginine8-vasopres-sin, 1283
Aldose reductase inhibitor, effects on mo-
tor nerve conduction, autonomiccardiac function, and nerve bloodflow, vs propionyl-L-carnitine, inrats with diabetes, 49
Alendronate, long-term
general safety and biomechanical prop-
erties of bone, in adult dogs, 271histomorphometric analysis of L5 verte-
brae, in adult dogs, 277Ali, H., Choi, 0. H., Fraundorfer, P. F.,
Yamada, K., Gonzaga, H. M. S.and Beaven, M. A. : Sustained ac-tivation of phospholipase D viaadenosine A3 receptors is associ-ated with enhancement of anti-gen- and Ca2�-ionophore-inducedsecretion in a rat mast cell line,837
Ali, M., Gawin, A. Z. and Baraniuk, J. N.:
Effects of bombesin family pep-tides and antagonists on guineapig nasal mucosal secretion, 1266
Alkana, R. L., see Davies, D. L., 667
A.lmazan, G., see Deng, X. F., 1155A.LN, see Alendronate
Alpha-a-acid glycoprotein, bupivacainebinding, human, 109
Alprazolam, effects on learning, monkeys
and rats, 1111Alternation behavior, spontaneous, dizo-
cilpine-induced, nitric oxide ef-fects in, in mice, 460
Amino acid modifying agents, and 12-imidazoline binding sites, 359
-y-Aminobutyric acidA receptorsdecreases in coupling sites, 519 cells, 882
striatal, effects ofrepeated cocaine injec-
tions, 10024-Amino- 1-hydroxybutylidene bisphos-
phonate, see Alendronate
2-[2-(4-Amino-3-iodophenyl)ethylamino-
]adenosine, ‘251-labeled, adeno-sine receptor binding, in coronary
artery, 284( ± )-2-Amino-N-( 1-methyl-1,2-diphenyl-
ethyl)acetamide, see Remacemide
Amnesia, dizocilpine-induced, nitric oxide
effects in, in mice, 460Amphetamine, stimulant sensitization,
phospholipase A2 mechanisms in,1244
Anderson, D. J., see Gopalakrishnan, M.,
289Anesthetics, actions on glutamate recep-
tors, 1058Angiotensin converting enzyme inhibitors,
inhibition in vivo, determinantsof, 708
Angiotensin IIreceptor antagonists, urate transporter
interactions, in rat renal brush-border membranes, 125
tachyphylaxis to, in rat mesentery invivo, 13
Animal models, of Parkinson’s disease,
ABT-431 effects in, 150
Antiarrhythmic drugsclass III, potassium channel block by,
intracellular magnesium effects,951
novel class III, dual actions, guinea pigheart, 1149
Anticoagulants, activated protein C ef-
fects, myocardial perfusion in-jury, canine, 1104
Antidepressants, long-term, effects on5-HT1D receptors, in rat midbrainraphe nuclei, 697
Antinociception
cannabinoid-induced, brain sites medi-
ating, in rats, 585cimetidine, 500
f3-endorphin systems, in periaqueductal
gray, biochemical and pharmaco-logical characterization, in rat, 65
from the periaqueductal gray, mediatedby spinal 5-hydroxytryptamine 1A
receptors, 958
induced by agonists of several receptors,cromakalim effects, 1136
morphine, nociceptive assay and, in ge-
netic models, 532supraspinal kappa opioid, 801
Antioxidants, cytoprotective actions of, in-
hibition ofreactive oxygen species
and cell injury, 1224Anxiolytics
putative mixed 5-HT1A agonist/5-HT2�2� antagonist, antipunish-ment effects, in pigeon, 388
1996 Index 1305
typical and atypical, effects on learning,
monkeys and rats, 1111
APE, see 2-[2-(4-Amino-3-iodophenyl)eth-
ylamino]adenosineAppleton, M. L., see Thornton-Manning,
J., 21Arbutin, depigmenting effects, in human
melanocytes, 765
L-A.rginine, analog effects on L-arginine-
nitric oxide pathway, in humanneutrophils and platelets, 253
Arginine8-vasopressin, ethanol combined
treatment, development of alco-hol tolerance after, rat, 1283
Arnaudeau, S., see Khac, L. D., 130Arneric, S. P., see Gopalakrishnan, M., 289
Arrhythmia, ventricular, BRL-32872 anti-arrhythmic profile, 637
Asaad, M. M., see Seymour, A. A., 708
Ascorbic acid, uptake, palytoxin effects,
bovine adrenal chromaffin cells,
996Asin, K. E., see Shiosaki, K., 150Astrocytoma, TXA2 receptor desensitiza-
tion in, in 1321N cells, 829Atrial natriuretic peptide, secretion,
erythropoietin stimulation of, rat
cardiac atrium, 1162Atrium, rat, atrial natriuretic peptide se-
cretion, erythropoietin stimula-tion of, 1162
Auer-Barth, S., see Leist, M., 968Autoradiography
MDMA-induced serotonin deficits, 855
NPY and CGRP modulation of sigma la-beling, in mouse brain, 223
Back, D. J., see Tjia, J. F., 912Baclofen, antinociception induced by, cro-
makalim effects, 1136Bader, J. P., see McMahon, J. B., 298Baeyens, J. M., see Oca#{241}a,M., 1136Baez, M., see Wainscott, D. B., 720
Balena, R., Markatos, A., Seedor, J. G.,Gentile, M., Stark, C., Peter, C. P.and Rodan, G. A. : Long-termsafety of the aminobisphospho-
nate alendronate in adult dogs.II. Histomorphometric analysis ofthe L5 vertebrae, 277
Banick, P. D., see Chen, Q., 929Baraldi, P. G., see Zocchi, C., 398Baraniuk, J. N., see Mi, M., 1266Barker, L. A., see Li, B. Y., 500Barnette, M. S., see Manning, C. D., 810Barrett, R. J., see Martin, P. L., 490Barrios, M., see Oca#{241}a,M., 1136Bartoszyk, G. D., Harting, J. and Minck,
K.-O.: Roxindole:
cological profile of a dopamine D2autoreceptor agonist, 41
Baruchel, S., see Wang, T., 1169Basbaum, A. I., see Gogas, K. R., 801Batist, G., see Wang, T., 1169Bauman, J. L., see Liu, D., 568Baumann, H., see Yoo, S. D., 918BAY X1005, myocardial protection by, 335Beaven, M. A., see Au, H., 837
Beck, G., see Ohlstein, B. H., 609Behavior
defensive-withdrawal, acute HU-210 ef-
fects on, mediation by corticotrop-in-releasing factor, in rats, 56
diazepam effects, hyperbaric antago-nism, in mice, 667
Behavioral sensitization, cocaine, x-opioidagonist effects on, 545
Bejanian, M., see Davies, D. L., 667
Belknap, J. K., see Mogil, J. S., 532Benjamin, C. W., see Taylor, B. M., 1224Benzodiazepine, chronic exposure, alloste-
ric uncoupling after, GABA recep-tor subtypes, 882
Benzodiazepine receptors, activity, viga-batrin modulation of, baboon, 977
Berger, S. P., see Reid, M. S., 1244
Bergman, J., Spealman, R. D., Madras, B.
K. and Rosenzweig-Lipson, S.:Agonist efficacy and the behav-
ioral effects of dopamine D1receptor ligands: Drug interac-tion studies in squirrel mon-keys, 942
Bernat, A., see Herbert, J. M., 1030Berti, F., see Rossoni, G., 335Bhatt, R. K., see Powell, W. S., 728Bianchi, B., see Shiosaki, K., 150Bigelow, G. E., see Eissenberg, T., 449Bile acid, multispecific transporter, drug
and steroid clearance, mamma-han liver, 891
Billingsley, M. L., see Thompson, T. A.,1201
Biphasic kinetics, theophylline, humanliver microsomes, 912
Birkett, D. J., see Tassaneeyakul, W., 101Bitar, K. N., Kothary, S. and Kothary, P.
C.: Somatostatin inhibits bomb-esin-stimulated Gi-protein via its
own receptor in rabbit colonicsmooth muscle cells, 714
Bixier, M. A., see Winsauer, P. J., 1 111
Blier, P., see Pi#{241}eyro, G., 697
Blood-brain barrierdouble-enkephalin analog, halogenated
derivatives and, 1049
[3H]-biotinylated phosphorothioate oh-godeoxynucleotide transport, 206
valproic acid uptake, medium-chainfatty acid transporter mediation
of, 1189Blood flow, nerve, effects of PCAL vs al-
dose reductase inhibitor on, inrats with diabetes, 49
BMS-180448, effects on postischemic re-
covery of contractile function, indogs, 380
Boado, R. J., see Wu, D., 206B#{246}hm,M., see Schwinger, R. H. G., 1180
Bolger, M. B., see Davies, D. L., 667
Bombesin, antagonists and, nasal mucosalsecretion and, guinea pig, 1266
Bone, biomechanical properties, with long-term alendronate, in adult dogs,271
Bonhomme, M., see Bril, A., 637Born, S. L., see Kraner, J. C., 258Bossuyt, X., MUller, M., Hagenbuch, B.
and Meier, P. J.: Polyspecific drugand steroid clearance by an or-ganic anion transporter of mam-mahian liver, 891
Bottlaender, M., see Schmid, L., 977
Bottorff, M. B., see Ujhelyi, M. R., 683
Bouchard, P., Roman, F., Junien, J.-L. andQuirion, R.: Autoradiographic ev-idence for the modulation of in
vivo sigma receptor labeling byneuropeptide Y and calcitonin
gene-related peptide in the mousebrain, 223
Boundy, B. A., Lu, L. and Mohinoff, P. B.:Differential coupling ofrat D2 do-pamine receptor isoforms ex-pressed in Spodoptera frugiperdainsect cells, 784
Boyd, M. R., see McMahon, J. B., 298BQ123, atrial natnuretic peptide secre-
tion and, rat cardiac atrium, 1162Brain
perfusion, valproic acid, fatty acid trans-
porter mediation of, 1189sigma receptors, in vivo labeling, modu-
lation by NPY and CGRP, in
mouse, 223
sites mediating cannabinoid-induced
antinociception, in rats, 585Breese, G. R., see Yang, X., 482Brett, C. M., see Chung, S.-J., 676Bril, A., Gout, B., Bonhomme, M., Lan-
dais, L., Faivre, J.-F., Linee, P.,Poyser, R. H. and Ruffolo, R. R.,Jr. : Combined potassium and cal-cium channel blocking activitiesas a basis for antiarrhythmic effi-cacy with low proarrhythmic risk:Experimental profile of BRL-32872, 637
Britton, D. R., see Shiosaki, K., 150BRL-32872, antiarrhythmic profile, 637
Brodie, M. S., see Trifunovi�, R. D., 342-a-Bromoisovalerylurea, conjugation, se-
hective inhibition of, 923Brouilhet, E., see Schmid, L., 977Brouwer, W. G., see McMahon, J. B., 298Brush-border membranes, All antagonist-
urate transporter interactions, in
rat kidney, 125Bryant, C. M., see Endemann, G., 5Buccellati, C., see Rossoni, G., 335Buckheit, R. W., Jr., see McMahon, J. B.,
298Bupivacaine, protein binding, human, 109Buprenorphine, physical dependence, in
humans, 449
Burnett, V. L., see Kraner, J. C., 258Burnstock, G., see King, B. F., 93Buspirone
antipunishment effects, in pigeon, 388effects on learning, monkeys and rats,
1111Bustamante, D., Paeile, C., Willer, J.-C.
and Le Bars, D.: Effects of intra-venous nonsteroidal antiinflam-
matory drugs on a C-fiber reflexelicited by a wide range of stimu-lus intensities in the rat, 1232
Cadmium chloride, hepatotoxicity, metal-lothionein role in, 1216
Calcineurin, inhibition by FK-506 analogs,
mixed agonistiantagonist activ-ity, 1078
Calcitonin gene-related peptide, modula-tion of sigma labeling by, inmouse brain, 223
Calciumcytosohic levels, LTB4 metabolite effects
on, 728
homeostasis, lipid A effects on, in renal
proximal tubules, 555indolactam-mediated contractions and,
resistance vessels, 867influx
1306 Index Vol. 276
and beta adrenergic receptor activa-
tion, in pregnant rat myome-trium, 130
carbamazepine blockade, in rat cere-bellar granule cells, 143
intracellular, vasorehaxing action of ru-taecarpine, vascular smooth mus-
cle and endothehial cells, 1016sensitization, by MCI-154, in guinea pig
heart, 433transients, MCI-154 effects on, in
guinea pig heart, 433Calmodulin, binding, ethanol inhibition,
glucocorticoid antagonism, 578
Calzadilla, S. V., see Opgenorth, T. J., 473Campbell, I. G. and Feinberg, I.: Noncom-
petitive NMDA channel blockadeduring waking intensely stimu-
hates NREM 5, 737
Cannabinoid, antinociceptive effects,brain sites mediating, in rats, 585
Cannabinoid receptors, CB1, immune ac-tivation and, 776
Cantor, C. R., see Hnatowich, D. J., 326Cao, L. S., see Mazoit, J. X., 109Capasso, A., Di Guannuario, A. , Loizzo, A.,
Pieretti, S., Sagratelha, S. andSorrentino, L. : Dexamethasoneselective inhibition ofacute opioid
physical dependence in isolated
tissues, 743
Carbamazepine, calcium influx blockadeby, in rat cerebellar granule cells,
143Cardiac function, autonomic, effects of
PCAL vs aldose reductase inhibi-
tor on, in rats with diabetes, 49Cardiovascular system, moxonidine, nh-
menidine and clonidine effects on,
imidazohine receptor interactions,in rabbits, 411
Cathow, J., see Ring, B. J., 658Cella, S. G., see De Gennaro Cohonna, V.,
795
Central nervous system, opioid receptors,effects in acute morphine immu-
nomoduhation, in rats, 626Cerebellar granule cells, Ca� � influx, car-
bamazepine blockade, in rat, 143Cerebral ischemia, focal, NBQX neuropro-
tection in, dose-response study, inrat, 1
Cerebrospinal fluid, saturable taunine dis-position in, in rat, 676
Cerebrum, neurogenic vasodilation, inhi-
bition by L-glutamine and NOS,353
Cenimele, B. J., see Ring, B. J., 658C-fiber reflex, wide range of stimulus in-
tensities, intravenous nonsteroi-
dal antiinflammatory drug ef-fects, rat, 1232
CGS 27830, binding properties, 74
CGS 18102A, antipunishment effects, inpigeon, 388
Chan, C. K. S., Sannajust, F. and Head, G.A.: Role of imidazoline receptorsin the cardiovascular actions ofmoxonidine, rilmenidine andclonidine in conscious rabbits,411
Chassaing, G., see Sagan, S., 1039
Chastain, M., see Hahn, R. A., 1104Chemtob, S., see Deng, X. F., 1155Chen, C-F., see Wang, G.-J., 1016
Chen, F. Y., see Lee, T. J.-F., 353Chen, J., see Graham, S. H., 1Chen, L. Y. and Mehta, J. L.: Variable
effects of L-arginine analogs on L-
arginine-nitric oxide pathway inhuman neutrophihs and plateletsmay relate to different nitric ox-ide synthase isoforms, 253
Chen, Q., Banick, P. D. and Thom, S. R.:Functional inhibition of rat pohy-
morphonuchear leukocyte B2 inte-grins by hyperbaric oxygen is as-sociated with impaired cGMP
synthesis, 929
Chen, X., see Wang, T., 1169Chen, Z., see Lash, L. H., 194Ch#{233}ramy, A., Godeheu, G., L’Hirondel, M.
and Glowinski, J.: Cooperative
contributions of chohinergic andNMDA receptors in the presynap-tic control of dopamine releasefrom synaptosomes of the rat stri-
atum, 616Chiba, S., see Imamura, H., 467
Chin, M. H., Cioffi, C. L., Garay, M.,Neale, R. F., Shetty, S. S., Del-
Grande, D., Mugrage, B., Sills, M.
A. and Lipson, K. E.: The unusualbinding properties ofthe endothe-lin receptor antagonist CGS
27830 distinguishes receptor/
agonist interactions, 74Chinese hamster ovary cells, human NK-1
receptors, tachykinin peptide ef-fects, 1039
Chinese herbal remedies, T2, IL-2 tran-scription suppression by, 316
Chiou, W. J., see Opgenorth, T. J., 473Chiu, N., Park, I. and Reid, I. A.: Stimu-
lation of remn secretion by thephosphodiesterase IV inhibitorrolipram, 1073
Chlordiazepoxide, effects on learning,monkeys and rats, 1111
Chloride current, acetylchohine-inducedoscillations, in swine tracheal
smooth muscle cells, 178
N-(2-Chloroethyh)-4-piperidinyl dipheny-
hacetate, quarternary transfor-mation products, muscaninic re-
ceptor binding, 405
N-(3-Chhoropropyl)-4-piperidinyh dipheny-
lacetate, quarternary transfor-mation products, muscarinic re-ceptor binding, 405
Choi, 0. H., see Ali, H., 837
Choo, K. H. A., see Liu, J., 1216Chou, C., see Low, R., 855
Chou, C.-J., see Wang, G.-J., 1016Christie, M. J., see Osborne, P. B., 137
Chuang, D.-M., see Hough, C. J., 143Chung, S.-J., Ramanathan, V. K., Brett, C.
M. and Giacomini, K. M.: Satura-ble disposition of taurine in therat cerebrospinal fluid, 676
Ciceni, S., see De Gennaro Colonna, V., 795
Cieshinski, L. B., see Manning, C. D., 810Cihiary ganglion, nicotimc receptor reduc-
tion by nereistoxin, whole chick
studies, 169Cimetidine
antinociceptive properties, 500uptake into syncytial microvillus mem-
brane vesicles, in human termplacenta, 219
Cioffi, C. L., see Chin, M. H., 74Cipris, S., see Pasyk, E. A., 690L-Citrulhine, reversal of L-glutamine and
NOS inhibition of cerebral neuro-
genic vasodilation by, 353Clomipramine, effects on ethanol-induced
excitation of ventral tegmentalarea dopaminergic neurons invitro, 34
Chonidineantinociception induced by, cromakahim
effects, 1136cardiovascular effects, imidazohine re-
ceptor interactions, in rabbits,
411growth hormone function effects, in
adult male rat, 795pretreatment, effects on naloxone-pre-
cipitated opiate withdrawal, 1128
Cocaineimmunosuppression induced by, metab-
ohism by cytochrome P-450 and,
1257
lidocaine interactions, 568
modification of serotonin responses by,
rat dorsolateral septal nucleusneurons, 1292
repeated administration, locomotor ac-tivity and, C57BL/6 mice, 904
repeated injections, effects on striatalGABA receptors, 1002
sensitization, K-opioid agonist effects on,545
stimulant sensitization, phosphohipase
A2 mechanisms in, 1244Coe, I. R., Dohrman, D. P., Constanti-
nescu, A., Diamond, I. and Gor-don, A. S.: Activation of cyclic
AMP-dependent protein kinase
reverses tolerance of a nucleosidetransporter to ethanol, 365
Cohen, J., see Porat, 0., 1162Cohen, M. L., see Cox, D. A., 1095Colbert, J., see Ijia, J. F., 912Colon, relaxation by somatostatin, in rab-
bit, 714
Constantinescu, A., see Coo, I. R., 365Conte, B., Cutrufo, C. and Manzini, S.:
Electrocorticographic desynchro-
nization after application of vis-cerah and somatic noxious stimuliin urethane-anesthetized rats:Effect of intrathecal administra-tion of tachykinin (NK 1 or NK 2)
receptor antagonists, 212Conti, A., see Zocchi, C., 398Contractile function, postischemic recov-
ery, BMS-180448 effects on, indogs, 380
Cook, S. A., see Lichtman, A. H., 585Coronary artery
adenosine receptor ‘251-APE binding,284
5-HT-induced contractions, enhance-ment by oxidized low-density li-poprotein, 1095
Corpus striatum synaptosomes, dopaminerelease, presynaptic control bychohinergic and NMDA receptors,in rat, 616
Correa, L. D., see Sacaan, A. I., 509Corticotropin-reheasing factor, mediation
of acute HU-210 effects on defen-sive-withdrawal behavior by, inrats, 56
1996 Index 1307
Cotreau-Bibbo, M. M., see von Moltke, L.
L., 370Cox, D. A. and Cohen, M. L.: Selective
enhancement of 5-hy-
droxytryptamine-induced con-traction of porcine coronary an-
tery by oxidized low-density
hipoprotein, 1095
Crawford, C. A., see Reid, M. S., 1244
CREB, see Cyclic AMP response element-binding protein
Cr#{233}pon,B., see Herbert, J. M., 1030CRF, see Corticotropin-releasing factorCriswehl, H. E., see Yang, X., 482Cromakalim, antinociception and, 1136Cryan, J., see Dumont, F. J., 1078
Cumming, P., see Li, B. Y., 500Currens, M. J., see McMahon, J. B., 298Cutrufo, C., see Conte, B., 212Cyanide, renal cellular ATP depletion by,
in distal tubule, 194Cyclic AMP, estradioh effects on, in rat pul-
monary vascular smooth muscle
cells, 652
Cyclic AMP-dependent protein kinase, re-versal of chronic ethanol effects
by, 365
Cyclic AMP response element-binding pro-
tein, regulation by morphine, in
nucleus accumbens, 306
Cyclic guanosine monophosphate, synthe-sis, hyperbaric oxygen and neu-
trophils, 929Cychophosphamide, cytochrome P450 sup-
pression by, in rat, 258Cytochrome P450
3A1, mRNA expression, forskolin-medi-ated induction of, in rat hepato-cytes, 238
cocaine metabolism by, immunosup-pression induced by, 1257
isoforms, toluene and xylene metabo-hism, human, 101
olanzapine metabolism, 658suppression by cyclophosphamide, in
rat, 258theophylline metabolism, human liver
microsomes, 912
vaccinia-expressed, 3-methyhindole me-tabohism by, 21
Cytoprotection, gastric mucosah cells and,
1174
Daaka, Y., Friedman, H. and Klein, T. W.:Cannabinoid receptor proteinsare increased in jurkat, humanT-celh line after mitogen activa-tion, 776
Dalby, N. 0. and Thomsen, C.: Modulation
of seizure activity in mice by
metabotropic glutamate receptorligands, 516
4-DAMP, see N,N-Dimethyl-4-piperidinyl
diphenylacetateDaniel, E. E., see Pasyk, E. A., 690Davies, D. L., Bejanian, M., Parker, E. S.,
M#{248}rland,J., Bolger, M. B. and Al-kana, R. L.: Low level hyperbaric
antagonism of diazepam’s loco-motor depressant and anticonvuh-sant properties in mice, 667
Davies, M. P., Freeman, L. C. and Kass, R.S. : Dual actions of the novel classIII antiarrhythmic drugNE-10064 on delayed potassiumchannel currents in guinea pig
ventricular and sinoatnial node
cells, 1149
Davis, L. S., see Tao, X., 316Davis, M. J., see Miniel, V., 867
Davis, T. P., see Abbruscato, T. J., 1049
Davis-Cox, M. I., Fletcher, T. L., Turner, J.N., Szarowski, D. and Sham, W.:
Three-day exposure to how-doseethanol alters guanine nucleotidebinding protein expression in thedeveloping rat hippocampus, 758
Dayton, B. D., see Opgenorth, T. J., 473
Defensive-withdrawal behavior, acuteHU-210 effects on, mediation bycorticotropin-releasing factor, inrats, 56
De Gennaro Cohonna, V., Zohi, M., Settem-brim, B. P., Ciceni, S., De Marco,
A., Cella, S. G., Agnati, L. F. andMuller, E. E.: Effects ofsingle and
short-term administration of
clonidine on hypothalamic-pitu-itary somatotropic function of theadult male rat: An in situ hybrid-
ization study, 795
Dejneka, N. S., see Thompson, T. A., 1201DeiGrande, D., see Chin, M. H., 74De Marco, A., see De Gennaro Colonna, V.,
795
Deng, X. F., Chemtob, S., Almazan, G. andVarma, D. R.: Ontogenic differ-ences in the functions of myocar-
dial alpha1 adrenoceptor sub-types in rats, 1155
Dependence, see also Tolerancephysical
acute opioid, dexamethasone effectson, 743
buprenorphine, in humans, 449
Desensitization, TXA� receptor, in 1321Nhuman astrocytoma cells, 829
Desipramine, altered disposition and anti-depressant activity, transgenicmice, 918
Dewey, M. J., see Yoo, S. D., 918
Dexamethasone, effects on acute opioidwithdrawal, 743
Diabetes, motor nerve conduction, auto-
nomic cardiac function, and nerveblood flow in, effects of PCAL vsaldose reductase inhibitor on, inrats, 49
Diabetes insipidus, lanreotide activity in,
rat, 875
Diagne, A., see Pardridge, W. M., 246Diamond, I., see Coe, I. R., 365Diazepam , hyperbaric antagonism, in
mice, 6679,10-Didehydro-N-(2-propynyl)-6-methyh-
ergohine-8b-carboxamide, seeLEK 8804
Didomenico, S., see Shiosaki, K., 150Di Guannuanio, A., see Capasso, A., 743meso-1,4-Dihydro-5-methoxycarbonyl-2,6-
dimethyl-4-(3-nitrophenyl)-3-pynidine carboxyhic acid anhy-dnide, see CGS 27830
2,3-Dihydroxy-6-nitro-7-suhfamoyl-benzo(F) quinoxahine, neuroprotectiveeffects in focal cerebral ischemia,
dose-response study, in rat, 1Dildy-Mayfield, J. E., Eger, E. I., II and
Harris, R. A.: Anesthetics pro-duced subunit-selective actionson glutamate receptors, 1058
N-(3,4-Dimethoxyphenyh)-N-[3[2-(3,4-di-methoxyphenyh)ethyh]propyl]-4-nitrobenzamide hydrochloride,see BRL-32872
N,N-Dimethyh-4-pipenidinyh diphenyhac-etate, analogs, muscannic recep-tor binding, 405
Dingaan, B., see Farhat, M. Y., 652Dionisotti, S., see Zocchi, C., 398Discrimination, see Drug discrimination
Dixon, D. B., see Opgenorth, T. J., 473Dizocihpine
effects on non-REM b EEG, 737-induced amnesia, nitric oxide effects in,
in mice, 460
DNA, esmTc4abeled phosphodiester vs
phosphorothioate, in vitro and inmice, 326
Dohrman, D. P., see Coe, I. R., 365Dol, F., see Herbert, J. M., 1030Donevan, S. D., see Subramaniam, S., 161Donnelly-Roberts, D., see Gopalakrishnan,
M., 289Dopamine
D1 receptor higands, agonist efficacy andbehavioral effects, 942
D2 receptor coupling, in S. frugiperdainsect cells, 784
release from synaptosomes, presynapticcontrol by chohinergic and NMDAreceptors, in rat striatum, 616
ventral tegmentah area neurons, etha-noh-induced excitation of, effectsof chomipramine on, in vitro, 34
Dopamine receptorsD1
effects in squirrel monkeys, 942persistent activation of, prolonged re-
ceptor desensitization and, 1022Dopamine reuptake inhibitors, locomotor
activity and, C57BL’6 mice, 904Dorsal horn neurons, nociceptive, periaq-
ueductal gray-induced inhibitionof, 5-HT3 receptors and, in rats,116
Dorso, C. R., see Seymour, A. A., 708
Dorsolaterah septah nucleus, modificationof serotonin responses in, acute
and chronic cocaine, rat, 1292Douglas, J. S., see Rhoden, K. J., 897Drug abuse, methcathione, effects on
monoaminergic systems, 1066
Drug conjugation, hepatic, total paren-terah nutrition effects on, in rats,602
Drug discrimination, nalbuphine, in rhe-sus monkeys, 523
Drug interaction studies, dopamine D1 re-ceptor higands, squirrel monkeys,942
Dunn, S. X., see von Moltke, L. L., 370
Duman, R. S., see Widnell, K. L., 306Dumont, F. J., Ok, H., Lin, S., Kastnen, C.
A., Cryan, J., Martin, M. M.,Wiederrech, G. and Staruch, M.J.: Mixed agonist/antagonist ac-tivity ofan FK-506-related immu-nosuppressant: Biological andbiochemical characterization,1078
Dunlop, J. L., see Sacaan, A. I., 509Dunn, C., see Yue, G., 265DX 9065A, effects, factor Xa, 1030Dykstra, L. A., see Fecho, K., 626
E-4031, vagolytic effects, in dogs, 467
1308 Index Vol. 276
Eddy, E. P., see Ohlstein, E. H., 609Edwards, J. W., see Tassaneeyakuh, W.,
101
Edwards, R. M., Trizna, W., Stack, E. J.and Weinstock, J.: Interaction ofnonpeptide angiotensin II recep-tor antagonists with the urate
transporter in rat renal brush-
border membranes, 125
Eger, E. I., II, see Dildy-Mayfiehd, J. E.,
1058
Ehhert, F. J., Oliff, H. S. and Griffin, M. T.:
The quarternary transformationproducts of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and
N-(2-chloroethyl)-4-pipenidinyl
diphenylacetate have differential
affinity for subtypes of the mus-carinic receptor, 405
EHNA, see Erythro-9-(2-hydroxy-3-nony-l)adenine
Eissenberg, T., Greenwald, M. K., John-son, R. E., Liebson, I. A., Bigelow,
G. E. and Stitzer, M. L.: Bu-prenorphine’s physical depen-dence potential: Antagonist-pre-cipitated withdrawal in humans,449
Electrocorticographic desynchronization,
effects of intrathecal tachykininson, in rats, 212
Ehectroencephahography, non-REM b, MK-
801 effects on, 737
Ellens, H., see Ohlstein, E. H., 609Elliott, J. D., see Ohlstein, E. H., 609Embolus imaging, two-step, galactose-
modified streptavidin-GC4 MAbconjugates for, 770
Endemann, G., Feng, Y., Bryant, C. M.,Hamilton, G. S., Perumattam, J.,Mewshaw, R. E. and Liu, D. Y.:Novel anti-inflammatory com-pounds prevent CD11b/CD18,aMP2 (Mac-1)-dependent neutro-phil adhesion without blocking
activation-induced changes inMac-i, 5
�-Endorphin, antinociceptive systems,periaqueductal gray, biochemicaland pharmacological character-ization, in rat, 65
Endothehial cells, K� channels in, VIP ef-
fects on, mediation by G protein,
690Endothehin receptors, antagonist SB
217242, pharmacological charac-
terization, 609EndothehinA receptors
antagonist A-127722, pharmacological
characterization, 473nociception mediation by, in mice, 647
EndothehinB receptors, nociception media-tion by, in mice, 647
Enflurane, actions on glutamate recep-tors, 1058
Enkephahin analog, blood-to-central ner-vous system entry, 1049
Epibatidine, effects on neurotransmitterrelease, in rats, 509
Erdmann, E., see Schwinger, R. H. G.,
1180Erythro-9-(2-hydroxy-3-nonyh)adenine,
hypoxic pulmonary vasoconstric-
tion reversal by, in rat hung, 752
Erythropoietin, stimulation, atrial natri-
uretic peptide secretion, rat car-diac atrium, 1162
Estradiol, effects on cAMP, in rat pulmo-nary vascular smooth musclecells, 652
Ethanolarginine8-vasopressin combined treat-
ment, development of alcohol toh-erance after, rat, 1283
chronic, tolerance to, reversal by cAMP-dependent protein kinase, 365
excitatory effects on ventral tegmentalarea dopaminergic neurons, ef-fects of clomipramine on, in vitro,34
glucocorticoid interactions, 578
low-dose, effects on guanine nucleotidebinding protein, in developing rathippocampus, 758
(±)-N-[(E)-4-Ethyl-3-[(Z)-hydroxyimino]-6-methyl-5-nitro-3-heptenyhl-3-pyridinecarboxamide, seeFR146801
(± )-(E)-4-Ethyl-2-[(E)-hydroxyiminol-5-
nitro-3-hexenamide, see FK409(±)-[(E)-4-Ethyl-3-[(Z)-hydroxyimino]-5-
nitro-3-hexenyl)-3-pynidinecar-boxamide, see FR144420
Factor Xa, DX 9065A inhibition of, 1030Faivre, J.-F., see Bril, A., 637Falck, J. R., see Powell, W. S., 728Fan, N. Y.-T., Powers, A. and Stier, C. T.,
Jr.: Lack of antidiuretic activityof hanreotide in the diabetes in-sipidus rat, 875
Farhat, M. Y., Abi-Younes, S., Dingaan,B., Vargas, R. and Ramwell, P.W. : Estradiol increases cyclicadenosine monophosphate in ratpulmonary vascular smooth mus-
cle cells by a nongenomic mecha-msm, 652
Farley, J. M., see Liu, X., 178Fatty acids, medium-chain, mediation of
valproic acid into rat brain, 1189
Fecho, K, Maslonek, K A., Dykstra, L. A.and Lysle, D. T. : Assessment ofthe involvement of central ner-vous system and peripheral opi-
oid receptors in the immuno-modulatory effects of acutemorphine treatment in rats, 626
Feigin, E., see Porat, 0., 1162Feinberg, I., see Campbell, I. G., 737Fehauer, E. E., see McMahon, J. B., 298
Feng, Y., see Endemann, G., 5FG 5974, antipunishment effects, in pi-
geon, 388Fibrin, galactose-modified streptavidin-
GC4 MAb conjugates, two-stepthrombus/embohus imaging appli-
cation, 770Fincher, T. K, see Yoo, S. D., 918
FK409, oral biological activities, 421FK-506 analogs, mixed agonist/antagonist
activity of, 1078
Fleming, W. E., see Taylor, B. M., 1224Fletcher, T. L., see Davis-Cox, M. I., 758
(2- 4-(4,4-bis(4-Fluorophenyh)butyl)- 1-
piperazinyl)-3-pynidinecarboxyhic
acid, see FG 5974Fogarasi, M., see Hnatowich, D. J., 326Folco, G. C., see Rossoni, G., 335
Follicular oocytes, P1 purinoceptors in, inx. laevis, 93
Fong, K-L., see Ohhstein, E. H., 609Forskohin, induction ofCYP3A1 mRNA ex-
pression by, in rat hepatocytes,238
FR144420, oral biological activities, 421FR146801, oral biological activities, 421France, C. P., see Gerak, L. R., 523Franklin, M. R., see Raftogianis, R. B., 602Fraundonfer, P. F., see Ahi, H., 837
Freel, R. W., see Hatch, M., 187
Freeman, L. C., see Davies, M. P., 1149
Friedman, H., see Daaka, Y., 776Fukuda, M., see Maeda, K, 765Fukuyama, S., see Rita, Y., 421
Furukawa, S., see Saita, K., 231Furukawa, Y., see Imamura, H., 467Furukawa, Y., see Saita, K., 231Fuseau, C., see Schmid, L., 977
GABA, see y-Aminobutyric acid
Gahactose-modified streptavidin-GC4
MAb conjugates, two-step throm-bus/embolus imaging application,
770
Galinsky, R. E., see Raftogianis, R. B., 602Gallager, D. W., see Primus, R. J., 882Gallagher, J. P., see Simms, D., 1292
Ganghion, ciliary, nicotinic receptor reduc-tion by nereistoxin, whole chickstudies, 169
Gao, X.-M., see Hough, C. J., 143Garay, M., see Chin, M. H., 74Gargalidis-Moudanos, C., see Tesson, F.,
359Gastric mucosah cells, cytoprotection and,
1174
Gastrin-releasing peptide, antagonistsand, nasal mucosah secretion and,guinea pig, 1266
Gawin, A. Z., see Mi, M., 1266Gehrke, L. J., see Opgenorth, T. J., 473Genetic models of opiate antinociception,
morphine sensitivity in, nocicep-tive assay and, 532
Gentile, M., see Balena, R., 277
Gerak, L. R. and France, C. P.: Discrimi-native stimulus effects of nalbu-phine in rhesus monkeys, 523
Gerber, J. G., see Payne, N. A., 984
Giacomini, K. M., see Chung, S.-J., 676Gibb, J. W., see Gygi, M. P., 1066Gillespie, T., see Ring, B. J., 658Glavin, G. B., Szabo, S., Johnson, B. R.,
Xing, P. L., Morales, R. E., Ple-bani, M. and Nagy, L.: Isolatedrat gastric mucosal cells: Optimalconditions for cell harvesting,measures of viability and directcytoprotection, 1174
Glennon, R. A., see Young, R., 594Glowinski, J., see Cheramy, A., 616Glucocorticoids, ethanol interactions, 578
Glutamate receptorsanesthetic actions on, 1058metabotropic higands, modulation of sei-
zures by, in mice, 516NMDA, subunits, striatal motor regula-
tion by, 342L-Ghutamine, inhibition of cerebral neuro-
genic vasodilation by, 353Glutathione
isoenzyme-selective inhibition of conju-
gation, rat, 923
1996 Index 1309
modulation by a cysteine pro-drug, en-hancement of tumor response,1169
Glycoprotein, alpha-i-acid, actions of imi-
pramine and, transgenic mice,918
Godeheu, G., see Cheramy, A., 616Gogas, K. R., Levine, J. D. and Basbaum,
A. I.: Differential contribution ofdescending controls to the antino-
ciceptive actions ofkappa and muopioids: An analysis of formalin-
evoked c-fos expression, 801Gonzaga, H. M. S., see Ali, H., 837
Gonzalez, F. J., see Thornton-Manning, J.,21
Gopalakrishnan, M., Monteggia, L. M.,
Anderson, D. J., Mohinari, E. J.,Piattoni-Kaplan, M., Donnelly-Roberts, D., Arneric, S. P. and
Sullivan, J. P.: Stable expression,pharmacologic properties andregulation ofthe human neuronalnicotinic acetylchohine a4f32 recep-tor, 289
Gordon, A. S., see Coe, I. R., 365Gout, B., see Bril, A., 637G protein
effects on 5-HT1D receptors, in rat mid-brain raphe nuclei, 697
mediation of VIP effects by, 690Graham, S. H., Chen, J., Lan, J. Q. and
Simon, R. P. : A dose-response
study of neuroprotection using
the AMPA antagonist NBQX inrat focal cerebral ischemia, 1
Gravel, S., see Powell, W. S., 728Greenblatt, D. J., see von Mohtke, L. L.,
370
Greene, J. R. T. and Mason, A.: Effects ofsomatostatin and related pep-tides on the membrane potentialand input resistance of rat yen-tral subicular neurons, in vitro,426
Greenwald, M. K., see Eissenberg, T., 449Griffin, M. T., see Ehlert, F. J., 405Grinnell, B. W., see Hahn, R. A., 1104Grover, G. J., Parham, C. S., Whigan, D.
B. and Mitroka, J. G. :180448, a novel glyburide-revers-
ible cardioprotective agent, en-
hances postischemic recovery of acontractile function in dogs, 380
Growth hormone
chonidine effects on, in situ hybridiza-tion study, in adult male rat, 795
lanreotide, hack of antidiuretic activityin diabetic rat, 875
Guanine nucheotide binding protein, low-
dose ethanol effects on, in devel-oping rat hippocampus, 758
Gulakowski, R. J., see McMahon, J. B., 298Gygi, M. P., Gibb, J. W. and Hanson, G. R.:
Methcathinone: An initial studyof its effects on monoaminergicsystems, 1066
Hagenbuch, B., see Bossuyt, X, 891Hahn, R. A., MacDonald, B. R., Chastain,
M., Grinnell, B. W. and Simpson,P. J.: Evaluation of activated pro-tom C on canine infarct size in anonthrombotic model of myocar-dial reperfusion injury, 1104
Hahogenation, double-enkephahin analog,blood-to-central nervous systementry, 1049
Halpert, J. R., see Kraner, J. C., 258
Hamada, Y., see Hotta, N., 49Hameedi, F. A., see Rosen, M. I., 1128Hamilton, G. S., see Endemann, G., 5Hammon, M. A., see Ring, B. J., 658Hanaoka, Y., see Saita, K., 231Hanson, G. R., see Gygi, M. P., 1066Hara, T., see Hotta, N., 49Harbon, S., see Khac, L. D., 130Hariman, R. J., see Liu, D., 568Harmatz, J. S., see von Moltke, L. L., 370Harrel, L. M., see von Moltke, L. L., 370Harris, R. A., see Dihdy-Mayfiehd, J. E.,
1058Harting, J., see Bartoszyk, G. D., 41
Hartnett, C., see Primus, R. J., 882Hasegawa, T., see Yamada, K., 460Hashefi, M., see Powell, W. S., 728Hashimoto, K., see Tao, X., 316Hashmi, M., see Rosebrough, S. F., 770
Hatanaka, K.-I., see Shimizu-Sasamata,
M., 84Hatch, M., Freel, R. W., Shahinfar, S. and
Vaziri, N. D.: Effects of the spe-cific angiotensin II receptor an-tagonist hosartan on urate ho-meostasis and intestinal urate
transport, 187Hawranko, A. A., see Monroe, P. J., 65
Hay, D. W. P., see Ohlstein, E. H., 609Hayashi, K, see Saita, K, 231Haynes, J., Jr., Kilhihea, D. W., Peterson,
P. D. and Thompson, W. J.:Erythro-9-(2-hydroxy-3-nonyl)ad-
enine inhibits cychic-3’,S’-guanosine monophosphate-stim-ulated phosphodiesterase toreverse hypoxic pulmonary vaso-constriction in the perfused rathung, 752
Head, G. A., see Chan, C. K. S., 411Heart
calcium sensitization by MCI-154 in, inguinea pig, 433
potassium current, NE-10064 actions
on, guinea pig, 1149
vagus control of, E-4031 effects on, indogs, 467
Heidbreder, Ch., see Shippenberg, T. S.,
545Hepatocytes, CYP3A1 mRNA expression,
forskohin-mediated induction of,in rat, 238
H#{233}rault, J. P., see Herbert, J. M., 1030Herbal remedies, T2, IL-2 transcription
suppression by, 316
Herbert, J. M., Bernat, A., Dol, F., Her-ault, J. P., Cr#{233}pon, B. andLormeau, J. C. : DX9065A, anovel, synthetic, selective andorally active inhibitor of FactorXa: In vitro and in vivo studies,
1030Hernandez, L., see Opgenorth, T. J., 473trans- 1 ,3,4,a5, iOb-Hexahydro 10-me-
thoxy-4-propyl-2H-( 1)benzoy-pyranoh[3,4-b]-pyridine, see CGS18102A
Hill, M. A., see Miriel, V., 867Hippocampus, guanine nucleotide binding
protein, low-dose ethanol effectson, in developing rat, 758
Hirasawa, Y., see Kita, Y., 421
Histaminegastric, pentagastrin-stimulated re-
lease, beta adrenoceptor stimula-tion effects, canine stomach, 984
homohogues, as H3 receptor ligands,
1009Histidine, regulation of 12-imidazohine
binding sites by, 359
HIV, see Human immunodeficiency virusHnatowich, D. J., Mardirossian, G., Foga-
rasi, M., Sano, T., Smith, C. L.,
Cantor, C. R., Rusckowski, M.and Winnard, P. , Jr. : Compara-tive properties of a technetium-99m-labehed single-stranded nat-ural DNA and a phosphorothioatederivative in vitro and in mice,
326
Hodges, L., see Shiosaki, K., 150
Hoeger, C., see Liapakis, G., 1089
Hohhaday, J. W., see Yoo, S. D., 918Hohhingsworth, Z. R., see Standaert, D. G.,
342Holsapple, M. P., see Jeong, T. C., 1257Hong, Y., see Shiosaki, K., 150
Hotta, N., Koh, N., Sakakibara, F., Naka-mura, J., Hamada, Y., Wakao, T.,
Hara, T., Mori, K., Naruse, K,
Nakashima, E. and Sakamoto,N.: Effect of propionyl-L-carnitine
on motor nerve conduction, auto-
nomic cardiac function, and nerveblood flow in rats with streptozo-tocin-induced diabetes: Compari-son with an aldose reductase in-
hibitor, 49
Hough, C. J., Irwin, R. P., Gao, X.-M., Ro-gawski, M. A. and Chuang, D.-M.:Carbamazepine inhibition of N-methyh-D-aspartate-evoked cal-cium influx in rat cerebehlar gran-uhe cells, 143
Hough, L. B., see Li, B. Y., 500Hoyano, Y., see Imamura, H., 467
H3 receptors, heterogeneity, histamine ho-mologues discriminating be-
tween, 1009Hruby, V. J., see Abbruscato, T. J., 1049Hsu, K., see Reid, M. S., 1244HU-210, acute effects on defensive-with-
drawal behavior, mediation by
CRF, in rats, 56Human immunodeficiency virus
infection, cationized hyperimmune im-munoghobuhin treatment of, in
hPBL-SCID mice, 246UC 38 effects against, 298
Hussain, T., Linden, J. and Mustafa, S. J.:
‘25I�pE binding to adenosine re-ceptors in coronary artery: Pho-
toaffinity labeling with 125I
azidoAPE, 284
Hydrogen-potassium-ATPase, inhibitors,relaxation of airway smooth mus-che, human and guinea pig, 897
8-Hydroxy-2-(di-n-propylamino)tetralin,see 8-OH-DPAT
5-Hydroxytryptamine
contractions induced by, porcine coro-nary artery, oxidized low-densityhipoprotein effects, 1095
MDMA-induced deficits
radiohigand binding and autoradiog-raphy studies, 855
1310 Index Vol. 276
synaptosomal uptake and tissue con-
centrations, 846
modification of responses, cocaine, rat
dorsolateral septal nucleus neu-
rons, 1292
5-Hydroxytryptamine1� receptors
agonisti5-HT�� antagonist anxiolytic
antipunishment effects, in pi-geon, 388
mediation, antinociception from theperiaqueductal gray, 958
5-Hydroxytryptamine1� receptors, regula-
tion in rat midbrain raphe nuclei,697
5-Hydroxytryptamine�2� receptors, an-
tagonist/5-HT1� agonist anxio-
lytic antipunishment effects, in
pigeon, 3885-Hydroxytryptamine25 receptors, phar-
macohogic characterization, 720
5-Hydroxytryptamine3 receptors, andperiaqueductah gray-induced in-hibition ofnociceptive dorsal hornneurons, in rats, 116
5-Hydroxytryptamine4 receptors, identifi-
cation, guinea pig stomach, 989Hyperbaric exposure, antagonism of diaz-
epam by, in mice, 667
Hypotension, moxonidine, rilmenidineand clonidine effects on, imidazo-
line receptor interactions, in rab-bits, 411
Hypothalamic-pituitary axis, somato-tropic function, clonidine effectson, in adult male rat, 795
Hypoxic pulmonary vasoconstriction, re-
versal by EHNA, in rat lung, 752
IBD, see Inflammatory bowel diseaseIL-2, seeImaging, two-step thrombus/embolus, ga-
lactose-modified streptavidin-GC4 MAb conjugates for, 770
Imamura, H., Furukawa, Y., Nakano, H.,Kasama, M. , Hoyano, Y. , andChiba, S.: Selective inhibition bya class III antiarrhythmic agent,
E-4031, of the negative chrono-tropic response to a parasympa-thetic stimulation in anesthetizeddogs, 467
Imidazohine receptorsagmatine and, in blood vessels, 1272
and cardiovascular effects of mox-
onidine, rilmenidine andclonidine, in rabbits, 411
12-Imidazohine, binding sites, amino acidmodifying agents and, 359
6-(1H-Imidazol-i-yl)-7-nitro-2,3-(H,4H)-quinoxahinedione hydrochloride,see YM9OK
Imipramine, altered disposition and anti-depressant activity, transgenicmice, 918
Immune activation, and CB1 cannabinoidreceptors, 776
Immunoglobulin, cationized hyperim-mune, phanmacokinetics, toxicityevaluation and treatment of HN-
infected hPBL-SCID mice, 246Immunomoduhation, acute morphine, in
rats, 626Immunosuppression
cocaine-induced, metabolism by cyto-chrome P-450 and, 1257
FK-506-related, mixed agonistIantago-nist activity of, 1078
Indolactam, contractions mediated by, cal-cium dependence of, resistancevessels, 867
Infection, HN, cationized hyperimmune
immunoglobuhin treatment of, in
hPBL-SCID mice, 246Inflammatory bowel disease, amelioration
by U74006F, in rats, 265
Inositol phosphates, generation, beta ad-renergic receptors and, in preg-
nant rat myometrium, 130Inotropic agents, enantioselective actions,
sodium channel activators, hu-
man myocardium, 1180Inotsume, N., see Ohtomo, T., 1143Integrmns, pohymorphonuclear leukocyte
B2 functional inhibition by hy-
perbaric oxygen, rat, 929aMP2 Integnins, upregulation, leumeclins
and, 5Interheukin-2, transcription, suppression
by T2, 316
Intestine, urate transport, hosantan effects
on, 187
Inui, K.-I., see Ohtomo, T., 1143lodoacetate, renal cellular ATP depletion
by, in distal tubule, 194Irwin, R. P., see Hough, C. J., 143Ischemia
focal cerebral, NBQX neuroprotectionin, dose-response study, in rat, 1
myocardial, contractile function recov-ery after, BMS-180448 effects on,
in dogs, 380
Ishine, T., see Lee, T. J.-F., 353Ishisu, R., see Abe, Y., 433
Isicka, A. M., see Abbruscato, T. J., 1049Isoenzymes, selective inhibition of gluts-
thione conjugation, rat, 923Isoflurane, actions on glutamate recep-
tors, 1058
Isoproterenol, stimulation, canine stom-
ach, pentagastric-stimulated his-tamine release and, 984
Jackson, E. K, see Tofovic, S. P., 13Jacoby, H. I., see Raffa, R. B., 647
Jenner, P., see Shiosaki, K., 150Jeong, T. C., Jordan, S. D., Matulka, R. A.,
Stanuhis, E. D., Park, S. S. and
Hohsapple, M. P.: Immunosup-pression induced by acute expo-sure to cocaine is dependent onmetabolism by cytoehrome P-450,1257
Johns, R. A., see Rengasamy, A., 30Johnson, B. R., see Glavin, G. B., 1174Johnson, R. E., see Eissenberg, T. , 449Jones, G. S., Jr., see Xie, Y., 169Jordan, S. D., see Jeong, T. C., 1257Junien, J.-L., see Bouchard, P., 223
Kainate, currents induced by, anesthetic
effects, Xenopus oocytes, 1058Kahant, H., see Wu, P. H., 1283Kamenka, J.-M., see Prinssen, E. P. M.,
904Kan, H., Ruan, Y. and Malik. K. U.: Local-
ization and characterization ofthe subtype(s) of muscarinic re-ceptor involved in prostacyclinsynthesis in rabbit heart, 934
Kang. Y.-S., see Pardridge, W. M., 246
Kasama, M., see Imamura, H., 467
Kass, R. S., see Davies, M. P., 1149Kastner, C. A., see Dumont, F. J., 1078Kathmann, M., see Leurs, R., 1009Kato, M., see Kits, Y., 421Kato, Y., see Kita, Y., 421Kawasaki-Yatsugi, S., see Shimizu-Sasa-
mata, M., 84Kest, B., see Mogil, J. S., 532Khac, L. D., Arnaudeau, S., Lepretre, N.,
Mironneau, J. and Harbon, S.:Beta adrenergic receptor activa-
tion attenuates the generation ofinositol phosphates in the preg-nant rat myometrium. Correla-tion with inhibition of Ca� � in-
flux, a cAMP-independentmechanism, 130
Khanapure, S. P., see Powell, W. S., 728Kidney, see also under Renal
brush-border membranes, All antago-
nist-urate transporter interac-tions, in rat, 125
Kilhilea, D. W., see Haynes, J., Jr., 752
King, B. F., Pintor, J., Wang, S., Zigan-shin, A. U., Ziganshina, L. E. andBurnstock, G.: A novel P1 purino-
ceptor activates an outward K�current in follicular oocytes of Xe-nopus laevis, 93
Rita, Y., Hirasawa, Y., Fukuyama, S., Oh-kubo, K., Kato, Y., Takamatsu,H., Ohno, M., Nishino, S., Kato,M. and Seki, J.: Oral biologicalactivities of spontaneous nitricoxide reheasers are accounted forby their nitric oxide-releasingrates and oral absorption man-
ners, 421
Klaassen, C. D., see Liu, J., 1216Klein, T. W., see Daaka, Y., 776
Kleven, M. S. and Kook, W.: Pharmacohog-
icah characterization of in vivoproperties of putative mixed5-HT1A agonist/5-HT�2� antago-nist anxiolytics. I. Antipunish-
ment effects in the pigeon, 388Kleven, M. S., see Prinssen, E. P. M., 904Koek, W., see Kieven, M. S., 388
Koek, W., see Prinssen, E. P. M., 904Koh, N., see Hotta, N., 49Komori, Y., see Yamada, K, 460Koob, G. F. , see Rodriguez de Fonseca, F.,
56Koshiya, K., see Shimizu-Sasamata, M., 84
Kostas, C., see Primus, R. J., 882Kosten, T. R., see Rosen, M. I., 1128Kothary, P. C., see Bitar, K N., 714
Kothary, S., see Bitar, K N., 714
Kraner, J. C., Morgan, E. T., Poet, T. S.,
Born, S. L., Burnett, V. L. andHahpert, J. R.: Suppression of rathepatic microsomal cytochromesP450 by cychophosphamide is cor-related with plasma thyroid hor-mone levels and displays differen-tial strain sensitivity, 258
Kreek, M. J., see Rosen, M. I., 1128Kursar, J. D., see Wainscott, D. B., 720
Kmvahue, for oxygen, of nitric oxide syn-thase, 30
Lago, A., see Ohistein, E. H., 609Lai, C. C., see Lee, T. J.-F., 353Lan, J. Q., see Graham, S. H., 1Lan#{231}a,A. J., see Wu, P. H., 1283Landais, L., see Bril, A., 637
1996 Index 1311
Lane, S. B., see Widnell, K. L., 306
Lanreotide, antidiuretic activity of, dia-
betic rat, 875
Lash, L. H., Tokarz, J. J., Chen, Z.,
Pedrosi, B. M. and Woods, E. B.:
ATP depletion by iodoacetate andcyanide in renal distal tubular
cells, 194
Lavielle, S., see Sagan, S., 1039Lazaroids, cytoprotective actions of, inhi-
bition of reactive oxygen species
and cell injury, 1224Learning, typical and atypical anxiolytic
effects, monkeys and rats, 1111
Le Bars, D. , see Bustamante, D., 1232Lee, T. J.-F., Sarwinski, S., Ishine, T., Lai,
C. C. and Chen, F. Y.: Inhibitionof cerebral neurogenic vasodila-
tion by L-glutamine and nitric ox-
ide synthase inhibitors and its re-versal by L-citrulhine, 353
LeFevour, A., see Shippenberg, T. S., 545Leist, M., Auer-Barth, S. and Wendel, A.:
Tumor necrosis factor production
in the perfused mouse liver and
its pharmacological modulation
by methylxanthines, 968
LEK 8804, antipunishment effects, in pi-geon, 388
Lepretre, N., see Khac, L. D., 130
Leukotriene B4, metabolite effects on neu-trophils, 728
Leumedins, and Mac-i upregulation, 5
Leurs, R., Kathmann, M., Volhinga, R. C.,
Menge, W. M. P. B., Schlicker, E.and Timmerman, H. : Histaminehomologues discriminating be-
tween two functional histamine
H3 receptor assays. Evidence forH3 receptor heterogeneity?, 1009
Levine, J. D., see Gogas, K. R., 801
Levine, M., see Morita, K., 996
Levofloxacin, transport, kidney epithelial
cell line, LLC-PK1, 1143
Low, R., Sabol, K. E., Chou, C., Vosmer, G.L., Richard, J. and Seiden, L. S.:Methylenedioxymethamphet-amine-induced serotonin deficitsare followed by partial recoveryover a 52-week period. Part II:
Radiohigand binding and autora-
diography studies, 855
Low, R., see Sabol, K. E., 846
Lewis, J. B., see Thompson, T. A., 1201
L’Hirondel, M., see Cheramy, A., 616
Li, B. Y., Naiwalk, J. W., Barker, L. A.,Cumming, P., Parsons, M. E. andHough, L. B.: Characterization ofthe antinociceptive properties of
cimetidine and a structural ana-
log, 500
Liapakis, G., Heoger, C., Rivier, J. and
Reisine, T. : Development of a se-
lective agonist at the somatosta-tin receptor subtype SSTR1, 1089
Lichtman, A. H., Cook, S. A. and Martin,B. R.: Investigation of brain sitesmediating cannabinoid-inducedantinociception in rats: Evidencesupporting periaqueductal gray
involvement, 585
Lidocaine, cocaine interactions, 568Liebson, I. A., see Eissenberg, T., 449
Limon, I., see Tesson, F., 359
Lin, C. W., see Shiosaki, K., 150
Lin, Q., Peng, B. and Willis, W. D.: Antino-ciception and inhibition from the
periaqueductal gray are mediatedin part by spinal
5-hydroxytryptamine1� recep-
tors, 958
Lin, Q., see Peng, Y. B., 116Lin, S., see Dumont, F. J., 1078Linden, J., see Hussain, T., 284
Linden, J., see Martin, P. L., 490Lindsay, T. J., see Ring, B. J., 658Linee, P., see Bril, A., 637Lipid A, effects on calcium homeostasis in
renal proximal tubules, 555
Lipkowski, A. W., see Abbruscato, T. J.,1049
Lipoprotein, oxidized how-density, en-hancement of 5-HT-induced con-tractions of porcine coronary ar-
tery, 1095Lipsky, P. E., see Tao, X., 316Lipson, K. E., see Chin, M. H., 74Liu, D., Hariman, R. J. and Bauman, J. L.:
Cocaine concentration-effect rela-tionship in the presence and ab-
sence of lidocaine: Evidence of
competitive binding between co-caine and hidocaine, 568
Liu, D. Y., see Endemann, G., 5Liu, J., Liu, Y., Michahska, A. E., Choo, K
H. A. and Klaassen, C. D.: Metal-lothionein plays less of a protec-
tive role in cadmium-metallothio-
nein-induced nephrotoxicity thanin cadmium chloride-induced
hepatotoxicity, 1216Liu, J.-F., see Wu, P. H., 1283Liu, X. and Farley, J. M.: Acetylchohine-
induced chloride current oscilla-
tions in swine tracheal smooth
muscle cells, 178
Liu, Y., see Liu, J., 1216Liver
drug conjugation, total parenteral nutri-tion effects on, in rats, 602
drug transport, polyspecific, 891
microsomes
theophylline metabolism in, human,
912
triazolam biotransformation, in vitro,
human, 370
septic failure, tumor necrosis factor pro-duction and methylxanthines,mouse, 968
tributylmethylammonium uptake, rat
plasma membrane vesicle stud-
ies, 561
Livi, G. P., see Manning, C. D., 810
LLC-PK1 cell line, transport of levofloxa-cm in, 1143
Lloyd, G. K., see Sacaan, A. I., 509Locomotor activity, diazepam effects on,
hyperbaric antagonism of, in
mice, 667Locus ceruleus, muscarinic and opioid cur-
rents, tetrahydro-9-aminoacri-
dine effects on, in rat neurons,
137
Loizzo, A., see Capasso, A., 743
Loring, R. H., see Xie, Y., 169
Lormeau, J. C., see Herbert, J. M., 1030
Losartan, effects on urate homeostasis
and intestinal urate transport,
187
Lu, L., see Boundy, B. A., 784
Lu, L., see Munir, M., 819Lumbar vertebrae, L5, histomorphometric
analysis, with hong-term ahendr-
onate, in adult dogs, 277Lung
hypoxic vasoconstniction, reversal byEHNA, in rat, 752
vascular smooth muscle cells, cAMP in,
estradiol effects on, in rat, 652
Luo, J., see Munir, M., 819Lyshe, D. T., see Fecho, K., 626
Mac-i, upregulation, leumedins and, 5
MacDonald, B. R., see Hahn, R. A., 1104Macleod, R. J., see Powell, W. S., 728
Maclouf, J., see Rossoni, G., 335
Madras, B. K., see Bergman, J., 942
Maeda, K. and Fukuda, M. : Arbutin:Mechanism of its depigmentingaction in human melanocyte cul-ture, 765
Magnesium, intracellular, potassium
channel block by class III antiar-rhythmic drug and, 951
Magnuson, S. R., see Opgenorth, T. J., 473Mahan, L., see Shiosaki, K., 150
Malik, K. U., see Kan, H., 934Manna, S., see Powell, W. S., 728Manning, C. D., McLaughlin, M. M., Livi,
G. P., Cieshinski, L. B., Torphy, T.J. and Bannette, M. S.: Prolongedbeta adrenoceptor stimulation up-regulated cAMP phosphodiester-
ase activity in human monocytes
by increasing mRNA and protein
for phosphodiesterases 4A and
4B, 810Manzini, S., see Conte, B., 212
Mardirossian, G. , see Hnatowich, D. J.,326
Markatos, A., see Balena, R., 277
Markel, M. L., see Ujhelyi, M. R., 683
Marsh, K. C., see Opgenorth, T. J., 473Martin, B. R., see Lichtman, A. H., 585
Martin, M. M., see Dumont, F. J., 1078Martin, P. L., Wysocki, R. J., Jr., Barrett,
R. J., May, J. M. and Linden, J.:Characterization of 8-(N-methyhi-sopropyh)amino-N6-(5’-endohy-
droxy-endonorbornyl)-9-methy-
ladenine (WRC-057i), a highly
potent and selective, non-xan-thine antagonist of A1 adenosine
receptors, 490
Maslonek, K. A., see Fecho, K., 626
Mason, A. , see Greene, J. R. T., 426Mast cells, phosphohipase D activation via
A3 receptors in, in rat, 837Mathews, W. R., see Taylor, B. M., 1224
Matsukura, S., see Saita, K., 231
Matsuyama, S., Sakiyama, H., Nei, K. and
Tanaka, C.: Identification of pu-
tative 5-hydroxytryptamine4 (5-
HT4) receptors in guinea pigstomach: The effect of TKS159, a
novel agonist, on gastric motility
and acetylchohine release, 989
Matulka, R. A., see Jeong, T. C., 1257May, J. M., see Martin, P. L., 490
Mayeux, P. R., see Proksch, J. W., 555
Maziere, M., see Schmid, L., 977
Mazoit, J. X., Cao, L. S. and Samii, K.:Binding of bupivacaine to human
serum proteins, isolated albumin
and isolated alpha-i-acid ghycop-
rotein. Differences between the
1312 Index Vol. 276
two enantiomers are partly due tocooperativity, 109
McGonigle, P., see Munir, M., 819
McHugh, T., see Xie, Y., 169
MCI-i54, calcium sensitization by, inguinea pig heart, 433
McKay, J., see Xie, Y., 169
McLaughlin, M. M., see Manning, C. D.,
810
McMahon, J. B., Buckheit, R. W., Jr., Gu-
lakowski, R. J., Currens, M. J.,
Vistica, D. T., Shoemaker, R. H.,
Stinson, S. F., Russell, J. D.,
Bader, J. P., Narayanan, V. L.,
Schultz, R. J., Brouwer, W. G.,
Fehauer, E. E. and Boyd, M. R.:
Biological and biochemical anti-
human immunodeficiency virus
activity of UC 38, a new non-
nucleoside reverse transcriptase
inhibitor, 298
McMahon, T. J., see Rosen, M. I., 1128
MDA, see 1-(3,4-Methylenedioxyphenyl)-
2-aminopropane
Medial septum, nicotinic acetylchohine re-
ceptors, 482
Mehta, J. L., see Chen, L. Y., 253Meier, P. J., see Bossuyt, X, 891
Meijer, D. K. F., see Mosehey, R. H., 561
Melanocytes, arbutin depigmenting ef-
fects, mechanism of action, 765
Mehe, P. C., see Winsauer, P. J., 1111
Melnychuk, D., see Wang, T., 1169
Menge, W. M. P. B., see Leurs, R., 1009
Menzaghi, F. , see Rodriguez de Fonseca,
F., 56
Menzaghi, F., see Sacaan, A. I., 509Merho-Pich, E. , see RodrIguez de Fonseca,
F., 56
Mesenteny, tachyphylaxis to angiotensin
II, in rat in vivo, 13
Messenger RNA, CYP3A1, expression, for-
skolin-mediated induction of, in
rat hepatocytes, 238
Mesylates, 21-aminosteroid tirilazad, IBD
amelioration by, in rats, 265
Metabotropic glutamate receptors, hi-gands, modulation of seizures by,in mice, 516
Metallothionein, protective role, cadmi-um-metallothionein-induced
nephrotoxicity, 1216
Methcathinone, effects on monoaminergicsystems, i066
Methoxamine, ontogenic differences infunction, myocardium, rat, 1155
N-Methyl-D-aspartate
channel blockade during waking, effectson NREM b, 737
-evoked Ca� � influx, carbamazepine
blockade, in rat cerebellar gran-ule cells, 143
receptors
glutamate, subunits, striatal motor
regulation by, 342
in NT2-N neurons, characterization,
819
presynaptic control of dopamine re-
lease by, in rat striatum synapto-
somes, 616
remacemide and des-glycine metabo-
hite blockade, 161
4-Methylcatechol, effects on recovery fromacrylamide neuropathy, 231
Methyhenedioxymethamphetamine, sero-
tonin deficits
radiohigand binding and autoradiogra-phy studies, 855
synaptosomal uptake and tissue concen-
trations, 846
i-(3,4-Methylenedioxyphenyl)-2-amin-opropane, R(-)- vs S(+ ) stimulus
effects, 5943-Methylindole, metabolism by vaccinia-
expressed P450 enzymes, 218-(N-Methylisopropyl)amino-N6-(5’-en-
dohydroxy-endonorbornyh)-9-methyhademne, see WRC-057i
Methylxanthine, pharmacology, tumor ne-crosis factor production and,
mouse liver, 968Mewshaw, R. E., see Endemann, G., 5Meyyappan, M., see Primus, R. J., 882Michaehides, M., see Shiosaki, K., 150Michahska, A. E., see Liu, J., 1216Microsomes, liver, triazolam biotransfor-
mation, in vitro, human, 370Mikusa, J., see Shiosaki, K, 150Miller, T., see Shiosaki, K, 150
Minck, K.-O., see Bartoszyk, G. D., 41
Miners, J. 0., see Tassaneeyakul, W., 101
Miriel, V., Zou, H., Davis, M. J., Song, J.and Hill, M. A.: Calcium depen-
dence of indolactam-mediatedcontractions in resistance vessels,867
Mironneau, J., see Khac, L. D., 130Miserendino, M. J. D., see Widnell, K. L.,
306Mitroka, J. G., see Grover, G. J., 380MK-801, see DizocilpineMogil, J. S., Kest, B., Sadowski, B. and
Behknap, J. K.: Differential ge-netic mediation of sensitivity tomorphine in genetic models of
opiate antinociception: Influenceof nociceptive assay, 532
Mohinari, E. J., see Gopalakrishnan, M.,
289
Mohinoff, P. B., see Boundy, B. A., 784
Molta, C., see Rossoni, G., 335Monoamine oxidase, I2-imidazohine bind-
ing sites, 359
Monoaminergic systems, methcathinone
effects, 1066
Monoclonal antibodies, galactose-modified
streptavidin-GC4 antifibrin con-
jugates, two-step thrombus/em-
bohus imaging application, 770
Monocytes, phosphodiesterase 4 isozymes,
810
Monopoli, A., see Zocchi, C., 398Monroe, P. J., Hawranko, A. A., Smith, D.
L. and Smith, D. J.: Biochemicaland pharmacological character-
ization of multiple /3-endorphin-ergic antinociceptive systems in
the rat periaqueductal gray, 65
Monteggia, L. M., see Gopalakrishnan, M.,289
Morales, R. E., see Glavin, G. B., 1174Morgan, E. T., see Kraner, J. C., 258Mori, K., see Hotta, N., 49Morita, K., Teraoka, K, Oka, M. and Le-
vine, M.: Inhibitory action of pa-
lytoxin on ascorbic acid transport
into cultured bovine adrenal chro-maffin cells, 996
M#{248}rland,J., see Davies, D. L., 667
Morphineacute, immunomoduhatory effects, in
rats, 626
antinociception induced by, cromakalimeffects, 1136
antinociceptive effects in genetic mod-els, nociceptive assay and, 532
CREB regulation by, in nucleus accum-bens, 306
Moseley, R. H., Smit, H., Van Solkema, B.
G. H., Wang, W. and Meijer, D. K.F.: Mechanisms for the hepaticuptake and bihiary excretion oftributylmethylammonium: Stud-ies with rat liver plasma mem-
brane vesicles, 561
Motor behavior, regulation, by NMDA glu-tamate receptor subunits, 342
Motor nerve conduction, effects of PCAL
vs aldose reductase inhibitor on,
in rats with diabetes, 49
Moxonidine, cardiovascular effects, imida-zoline receptor interactions, inrabbits, 411
Mugrage, B., see Chin, M. H., 74Mulder, G. J., see Ouwerkerk-Mahadevan,
S., 923
Muller, M., see Bossuyt, X, 891
Muller, E. E., see De Gennaro Cohonna, V.,795
MUller-Ehmsen, J., see Schwinger, R. H.
G., 1180Mulher-Peddinghaus, R., see Rossoni, G.,
335Munir, M., Lu, L., Wang, Y.-H., Luo, J.,
Wolfe, B. B. and McGonigle, P.:Pharmacological and immunolog-
ical characterization of N-methyl-
D-aspartate receptors in human
NT2-N neurons, 819
Murase, K., see Shimizu-Sasamata, M., 84Muscarinic receptors
4-DAMP analog binding, 405subtypes of, prostacyclin synthesis, rab-
bit heart, 934
tetrahydro-9-aminoacridine effects on,in rat hocus ceruleus neurons, 137
Muscle, see Smooth muscleMustafa, S. J., see Hussain, T., 284
Myocardial infarction, activated protein C
effects on infarct size, canine non-
thrombotic model, 1104Myocardial ischemia, contractile function
recovery after, BMS-180448 ef-
fects oi, in dogs, 380
Myocardium
protection by BAY Xi005, 335sodium channel activators, enantios-
elective inotropic actions of, 1180Myometrium, inositol phosphate genera-
tion, beta adrenergic receptors
and, in pregnant rat, 130
Nabeshima, T., see Yamada, K., 460
Nachshon, S., see Porat, 0., 1162Nagy, L., see Glavin, G. B., 1174Nakahata, N., see Sakai, K., 829Nakamura, J., see Hotta, N., 49Nakano, H., see Imamura, H., 467Nakano, T., see Abe, Y., 433Nakashima, E., see Hotta, N., 49Nalbuphine, discriminative stimulus ef-
fects, in rhesus monkeys, 523
Naloxone, opiate withdrawal precipitated
by, clonidine pretreatment ef-
fects, 1128
1996 Index 1313
Nalwahk, J. W., see Li, B. Y., 500Nambi, P., see Ohlstein, E. H., 609
Narayanan, V. L., see McMahon, J. B., 298
Narimatsu, A., see Abe, Y., 433Naruse, K., see Hotta, N., 49Nasal mucosa, secretion, effects of bomb-
esin family peptides and antago-
nists on, 1266Navarro, M. , see RodrIguez de Fonseca, F.,
56
NBQX, see 2,3-Dihydroxy-6-nitro-7-sulfa-moyl-benzo (F) quinoxaline
NE-i0064, dual actions, guinea pig yen-
tricular and sinoatrial node cells,1149
Neale, R. F., see Chin, M. H., 74Negretti, A., see Zocchi, C., 398Nei, K., see Matsuyama, S., 989
Nelson, D. L., see Wainscott, D. B., 720Neostriatum, motor regulation, by NMDA
glutamate receptor subunits, 342
Nephrotoxicity, Cd-metallothionein, met-
ahlothionein protective role in,
1216
Nereistoxin, metabohite, mcotinic receptor
reduction by, whole chick ciliaryganglion studies, 169
Nerve blood flow, effects ofPCAL vs aldose
reductase inhibitor on, in rats
with diabetes, 49
Nestler, E. J., see Widnell, K. L., 306Neumann, D., see Porat, 0., 1162Neurogenic vasodilation, cerebral, inhibi-
tion by L-glutamine and NOS, 353
Neurokinin 1 receptors, intrathecal antag-
onist effects on electrocortico-
graphic desynchronization, inrats, 212
Neurokinin 2 receptors, intrathecal antag-
onist effects on electrocortico-
graphic desynchronization, in
rats, 212
Neuromedin B, nasal mucosal secretion
and, guinea pig, 1266Neuropathy, acrylamide-induced, recov-
ery from, 4-methylcatechol effects
on, 23i
Neuropeptide Y, modulation of sigma ha-
beling by, in mouse brain, 223
Neurotoxicity, selective, induction of apop-tosis by organotin compounds,
i2Oi
Neurotransmitters, release, epibatidine
effects on, in rats, 509
Neutral endopeptidase 3.4.24.li, inhibi-tion in vivo, determinants of, 708
Neutrophils
L-arginine-nitnic oxide pathway, L-
arginine analog effects on, in hu-
man, 253
LTB4 metabolite effects on, 728
Mac- i-dependent adhesion, leumedinblockade, 5
Nicotinic acetylcholine receptors
a4132, expression, pharmacologic proper-ties and regulation, 289
agonist epibatidine, effects on neuro-
transmitter release, in rats, 509
neural effects in medial septum, 482
reduction by nereistoxin, whole chickciliary ganglion studies, 169
Nikai, T., see Yamada, K., 460Nikkel, A., see Shiosaki, K., 150
Nishino, S., see Kita, Y., 421
Nitric oxide
effects in dizocilpine-induced impair-
ment of spontaneous alternation
behavior, in mice, 460
spontaneous releasers, oral biologicalactivities, 421
synthesis of, L-arginine analog effects
on, in human neutrophihs and
platelets, 253
Nitric oxide synthase
inhibitors, inhibition of cerebral neuro-
genic vasodilation by, 353Kmvahue for oxygen of, 30
Nociception, endothehin-induced, in mice,647
Nociceptive assay, and morphine antinoci-ception in genetic models, 532
Nociceptive dorsal horn neurons, periaq-ueductal gray-induced inhibitionof, 5-HT3 receptors and, in rats,116
Noda, Y., see Yamada, K., 460Non-rapid eye movement sleep 8, MK-80i
effects on, 737
Nonsteroidal antiinflammatory agents, in-
travenous, effects on C-fiber re-
flex, rat, 1232Norepinephrine, ontogenic differences in
function, myocardium, rat, 1155
Novosad, E. I., see Opgenorth, T. J., 473NREM, see Non-rapid eye movement
NT2-N neurons, NMDA receptors in, char-
acterization, 819Nucleus accumbens, CREB regulation by
morphine in, 306
Oca#{241}a,M., Barrios, M. and Baeyens, J. M.:Cromakalim differentially en-hances antinociception induced
by agonists of alpha2 adrenocep-tons, y-aminobutyric acid B. Muand Kappa opioid receptors, 1136
8-OH-DPATantipunishment effects, in pigeon, 388
effects on learning, monkeys and rats,liii
Ohi, T., see Saita, K., 231
Ohizumi, Y., see Sakai, K., 829
Ohkubo, K., see Kita, Y., 421
Ohlstein, E. H., Nambi, P., Lago, A., Hay,
D. W. P., Beck, G., Fong, K-L.,Eddy, E. P., Smith, P., Ellens, H.and Elliott, J. D.: Nonpeptide en-dothehin receptor antagonists. VI:Pharmacological characterizationofSB 217242, a potent and highlybioavaihable endothehin receptorantagonist, 609
Ohmori, J., see Shimizu-Sasamata, M., 84
Ohno, M., see Rita, Y., 421Ohtomo, T. , Saito, H., Inotsume, N., Yasu-
hara, M. and Inui, K-I.: Trans-
port of levofloxacin in a kidney
epithelial cell line, LLC-PK1: In-
teraction with organic cationtransporters in apical and baso-
lateral membranes, 1143Ok, H., see Dumont, F. J., 1078Oka, M., see Morita, K., 996Okada, M., see Shimizu-Sasamata, M., 84
Ohanzapine, cytochromes P450 metabo-lism, 658
Ohiff, H. S., see Ehlert, F. J., 405Oligodeoxynucleotide, [3H]-biotinylated
phosphorothioate, pharmacoki-
netics and blood-brain barrier
transport, 206
Omeprazole, relaxation, airway smoothmuscle, human and guinea pig,
897
Omiecinski, C. J., see Sidhu, J. S., 238
Ongini, E., see Zocchi, C., 398Onishi, K., see Abe, Y., 433Ono, H., see Sakai, K., 829
Opgenorth, T. J., Adler, A. L., Cahzadilla,
S. V., Chiou, W. J., Dayton, B. D.,
Dixon, D. B., Gehrke, L. J., Her-nandez, L., Magnuson, S. R.,
Marsh, K. C., Novosad, E. I., Von
Geldern, T. W., Wessale, J. L.,Winn, M. and Wu-Wong, J. R.:Pharmacological characterization
ofA-i27722: An orally active and
highly potent ETA-selective re-
ceptor antagonist, 473
Opioid receptorsdelta, spinal, analgesic potency, in am-
phibians, 440
effects in acute morphine immunomodu-
hation, in rats, 626
kappa
agonists, effects on sensitization to co-
caine, 545
spinal, analgesic potency, in amphib-
ians, 440
supraspinal, antinociceptive effects,
801
mu, spinal, analgesic potency, in am-
phibians, 440
tetrahydro-9-aminoacridine effects on,
in rat locus ceruheus neurons, 137
Opioidswithdrawal
dexamethasone effects on, 743
naloxone-precipitated, clonidine pre-
treatment effects, 1128
Organic anions, transporter, drug and ste-roid clearance, mammalian liver,891
Organic cationshepatic transport, rat liver plasma
membrane vesicle studies, 561secretion, enhancement by urine acidifi-
cation, 683
Osborne, P. B. and Christie, M. J.: Tetra-
hydro-9-aminoacridine has mixedactions on muscarinic currents
and blocks opioid currents in rat
hocus ceruheus neurons, 137
Ouwerkerk-Mahadevan, S. , vanBoom, J.H. and Mulder, G. J.: Isoenzyme-selective inhibition of ghutathione
conjugation in vivo: Selective in-hibition of the conjugation of S-2-
bromoisovaleryhurea in the rat,
9232-L-Oxothiazohidine carboxyhate, enhance-
ment of tumor response, moduha-
tion of glutathione by, 1169
Oxygenhyperbaric, functional inhibition of rat
polymorphonuclear heukocyte B2
integrins by, 929
Kmvalue for, of nitric oxide synthase, 30
Paeile, C., see Bustamante, D., 1232
Palytoxin, inhibitory action, ascorbic acid
transport, bovine adrenal chro-maffin cells, 996
Pang, P. K. T., see Wang, G.-J., 1016Parasympathetic nervous system, stimu-
lation of, cardiac responses,E-403i effects on, in dogs, 467
1314 Index Vol. 276
Pardridge, W. M., Kang. Y.-S., Diagne, A.and Zack, J. A.: Cationized hyper-
immune immunoglobulins: Phar-
macokinetics, toxicity evaluation
and treatment of human immu-
nodeficiency virus-infected hu-
man-peripheral blood lympho-
cytes-severe combined immune
deficiency mice, 246
Pardridge, W. M., see Wu, D., 206Parenteral nutrition, total, effects on he-
patic drug conjugation, in rats,
602
Parham, C. S., see Grover, G. J., 380
Parini, A., see Tesson, F., 359
Park, I., see Chiu, N., 1073
Park, S. S., see Jeong, T. C., 1257
Parker, E. S., see Davies, D. L., 667
Parkinson’s disease
ABT-431 effects in, in animal models,
150
dopamine D1 receptor effects, receptordesensitization, studies with
A-77636, 1022
Parsons, M. E., see Li, B. Y., 500
Pasyk, E. A., Cipris, S. and Daniel, E. E.: A
G protein, not cyclic AMP, medi-ates effects of VIP on the in-
wardly K� channels in endothe-
hal cells, 690
Payne, N. A. and Gerber, J. G.: The effect
of beta adrenoceptor stimulation
of canine stomach on pentagas-
trin-stimulated histamine re-
lease, 984
PCAL, See Propionyh-L-carnitine
Pearsall, H. R., see Rosen, M. I., 1128
Pedrosi, B. M., see Lash, L. H., 194
Peereboom-Stegeman, J. H. J. C. , see Aa,
E. M. van der, 219
Peng, B., see Lin, Q., 958
Peng, Y. B., Lin, Q. and Willis, W. D.: Therole of 5-HT3 receptors in periaq-
ueductal gray-induced inhibition
of nociceptive dorsal horn neu-
rons in rats, 116
Pentagastrin, histamine release stimu-
hated by, beta adrenoceptor stim-ulation effects, canine stomach,
984
Pentoxifylhine, pharmacology, tumor ne-
crosis factor production and,
mouse liver, 968
Periaqueductal grayantinociception and inhibition from, me-
diated by spinal 5-hy-
droxytryptamine 1A receptors,
958
�-endorphin antinociceptive systems,
biochemical and pharmacological
characterization, in rat, 65
inhibition of nociceptive dorsal horn
neurons, 5-HT3 receptors and, in
rats, 116
sites mediating cannabinoid-induced
antinociception, in rats, 585
Peripheral nervous system, opioid recep-
tors, effects in acute morphine
immunomoduhation, in rats, 626
Peris, J. : Repeated cocaine injections de-
crease the function of stniatal
y-aminobutynic acidA receptors,
1002
Perumattam, J. , see Endemann, G. , 5
Peter, C. P., Guy, J., Shea, M., Bagdon, W.,Kline, W. F. and Hayes, W. C.:Long-term safety of the ami-nobisphosphonate ahendronate in
adult dogs. I. General safety and
biomechanical properties of bone,271
Peter, C. P., see Balena, R., 277Peterson, P. D., see Haynes, J., Jr., 752Phenylephrine, ontogenic differences in
function, myocardium, rat, 1155
7-(2-Phenylethyl)-5-amino-2-(2-furyh)-
pyrazolo-[4,3-e]- 1 ,2,4-tria-
zolo[i,5-c]pyrimidine, see SCH
58261
Phosphodiesterase, inhibition by EHNA,
and hypoxic pulmonary vasocon-striction reversal, in rat lung, 752
Phosphodiesterase 4, isozymes in human
monocytes, 810
Phosphodiester DNA, 9SmTc�labeled, invitro and in mice, 326
Phosphoidesterase, inhibitor rohipram,
stimulation of renin secretion,
1073
Phosphohipase A2, mechanisms, involve-
ment in development of stimulantsensitization, 1244
Phosphohipase D, activation via A3 recep-
tors, in rat mast cells, 837
Phosphorothioate DNA, BBmTc�labeled, invitro and in mice, 326
Phosphorothioate oligodeoxynucleotides,
[3H1-biotinylated, pharmacoki-netics and blood-brain barrier
transport, 206
Physical dependence
acute opioid, dexamethasone effects on,
743
buprenorphine, in humans, 449
Piattoni-Kaphan, M., see Gopalakrishnan,M., 289
Pieretti, S., see Capasso, A., 743
Pigment, arbutin effects, in human meha-nocytes, 765
Pi#{241}eyro, G. and Blier, P.: Regulation of5-hydroxytryptamine releasefrom rat midbrain raphe nuclei by
5-hydroxytryptamine receptors:Effect of tetrodotoxin, G proteininactivation and long-term anti-depressant administration, 697
Pintor, J., see King, B. F., 93
Piperidine, repeated administration, loco-
motor activity and, C57BL/6
mice, 904
Placenta, term, cimetidine uptake intosyncytial microvillus membrane
vesicles, in human, 219
Platelets, L-arginine-mtric oxide pathway,
L-arginine analog effects on, in
human, 253Phebani, M., see Glavin, G. B., 1174Poet, T. S., see Kraner, J. C., 258Polavarapu, R., see Thompson, T. A., 1201Porat, 0., Neumann, D. Zamir, 0., Nachs-
hon, S., Feign, E., Cohen, J. and
Zamir, M.: Erythropoietin stimu-hates atrial natriuretic peptide se-
cretion from adult rat cardiacatrium, 1162
Positron emission tomography, vigaba-
tnin, modulation of benzodiaz-
epine receptor activity, baboon,977
Potassium channels, VIP effects on, medi-
ation by G protein, 690
Potassium current, ventricular and sino-
atrial node cells, dual actions ofnovel class III antiarrhythmic
drug NE-10064, 1149
Powell, W. S., Rokach, J., Khanapure, S.P., Manna, S., Hashefi, M., Gray-eh,S., Macleod, R. J., Falck, J. R.
and Bhatt, R. K.: Effects of me-
tabohites of leukotriene B4 on hu-
man neutrophil migration and cy-tosohic calcium levels, 728
Powers, A., see Fan, N. Y.-T., 875
Poyser, R. H., see Bril, A., 637
Pradier, L.., see Sagan, S., 1039
Prazosin, antipunishment effects, in pi-geon, 388
Pregnant myometrium, inositol phosphate
generation, beta adrenergic re-ceptors and, in rat, 130
Primus, R. J., Yu, J., Xu, J., Hartnett, C.,
Meyyappan, M., Kostas, C., Ram-
abhadran, T. V. and Gallager, D.W.: Allosteric uncoupling afterchronic benzodiazepine exposureof recombinant -y-aminobutynic
acidA receptors expressed in Sf��cells: Ligand efficacy and subtype
selectivity, 882Prinssen, E. P. M., Kleven, M. S., Vignon,
J., Kamenka, J.-M. and Koek,
Effects of repeated administra-tion of N-[i-(2-benzo(b)-thiophe-
nyl)cyclohexyhlpiperidine and co-
caine on locomotor activity inC57BL/6 mice, 904
Pritchard, G. A., see von Mohtke, L. L., 370
Proksch, J. W., Traylor, L. A. and Mayeux,
P. R.: Effects ofhipid A on calciumhomeostasis in renal proximal tu-
bules, 555
Propionyl-L-cannitine, effects on motornerve conduction, autonomic car-diac function, and nerve bloodflow, vs aldose reductase inhibi-tor, in rats with diabetes, 49
Prostacychin, synthesis, muscarinic recep-ton involved in, rabbit heart, 934
Prostaglandins, direct cellular protection
by, gastric mucosal cells, 1174
Protein C, activated, infarct size in caninemodel of myocardial reperfusioninjury, 1104
Protein kinase C, activator, contractionsmediated by, resistance vessels,867
Proteins
Geffects on 5-HT1D receptors, in rat
midbrain raphe nuclei, 697mediation of VIP effects by, 690
serum, bupivacaine binding, human,
i09Pulmonary vasoconstriction, hypoxic, re-
versal by EHNA, in rat lung, 752Purinoceptors, Pi. folhicular oocyte, X. lae-
vis, 93Pyridonecarboxyhic acid, transport, LLC-
PKi cell line, 1143N-(29(4-(2-Pynimidinyl)-i-piperazinyh)eth-
yl)tricyclo(3.3.i.i(3,7)) decane-i-carboxamide, see WY 50,324
2 i-(4-(2,6-di- 1-Pyrrohidinyl-4-pynimidi-
nyh)-i-piperazinyl)-16 alpha-
1996 Index 1315methyl-pregna-i,4,9(1 1)-triene-
3,20-dione, see U74006F
Quirion, R., see Bouchard, P., 223
Raasch, W., see Regunathan, S., 1272
Raffa, R. B., Schupsky, J. J. and Jacoby, H.
I.: Endothehin-induced nocicep-tion in mice: Mediation by ETA
and ETB receptors, 647Raftogianis, R. B., Franklin, M. R. and
Galinsky, R. E.: Effect of lipid-
free total parenteral nutrition onhepatic drug conjugation in rats,602
Ramabhadran, T. V., see Primus, R. J., 882Ramanathan, V. K., see Chung, S.-J., 676Ramwelh, P. W., see Farhat, M. Y., 652
Raphe nuclei, 5-HT1D receptors, regula-tion of, in rat midbrain, 697
Reactive oxygen species, cell injury and,cytoprotective actions of haz-aroids, 1224
Receptorsacetylchohine, presynaptic control of do-
pamine release by, in rat stria-
tum synaptosomes, 616adenosine, ‘25I-APE binding, in coro-
nary artery, 284adenosine A1 antagonist WRC-0571,
characterization, 490adenosine A2a, antagonist SCH 58261,
pharmacological profile, 398adenosine A3 phospholipase D activa-
tion via, in rat mast cells, 837angiotensin II, antagonists, urate trans-
porter interactions, in rat renal
brush-border membranes, 125cannabinoid CBi, immune activation
and, 776dopamine: see Dopamine receptorsendothehin, antagonist SB 217242, phar-
macological characterization, 609endothelinA
antagonist A-127722, pharmacohogi-cal characterization, 473
nociception mediation by, in mice, 647endothehinB nociception mediation by,
in mice, 647glutamate
metabotnopic higands, modulation ofseizures by, in mice, 5i6
NMDA, subunits, striatal motor regu-lation by, 342
5-HT1A, agonist/5-HT2�2� antagonistanxiohytic antipunishment ef-fects, in pigeon, 388
5-HT1D, regulation in rat midbrain na-phe nuclei, 697
5-HT2�2�, antagonisti5-HT1� agonistanxiolytic antipunishment ef-fects, in pigeon, 388
5-HT2B, pharmacologic characteriza-tion, 720
5-HT3, and periaqueductal gray-inducedinhibition of nociceptive dorsalhorn neurons, in rats, 1 i6
imidazohine, and cardiovascular effectsof moxonidine, nilmenidine and
chonidine, in rabbits, 411muscarinic
4-DAMP analog binding, 405tetrahydro-9-aminoacnidine effects
on, in rat hocus ceruleus neurons,
137
neurokinin 1, intrathecal antagonist ef-
fects on electrocorticographic de-synchronization, in rats, 2i2
neurokinin 2, intrathecal antagonist ef-
fects on ehectrocorticographic de-synchronization, in rats, 212
nicotinic acetyhchohinea4132, expression, pharmacologic prop-
erties and regulation, 289agonist epibatidine, effects on neuro-
transmitter release, in rats, 509
neural effects in medial septum, 482
reduction by nereistoxin, whole chickcihiary ganghion studies, 169
NMDAglutamate, subunits, striatal motor
regulation by, 342in NT2-N neurons, characterization,
819
presynaptic control of dopamine re-lease by, in rat striatum synapto-somes, 616
remacemide and des-glycine metabo-hite blockade, 161
opioid
delta, spinal, analgesic potency, in
amphibians, 440effects in acute morphine immuno-
modulation, in rats, 626kappa
spinal, analgesic potency, in am-phibians, 440
supraspinal, antinociceptive effects,
801
mu, spinal, analgesic potency, in am-phibians, 440
tetrahydro-9-aminoacridine effectson, in rat locus ceruleus neurons,137
purinergic, P1, folhicular oocyte, X. lae-vis, 93
sigma, in vivo labeling, modulation byNPY and CGRP, in mouse brain,223
thromboxane A2 desensitization, ini321N human astrocytoma cells,829
Regunathan, S., Youngson, C. , Raasch,W., Wang, H. and Reis, D. J.: Imi-dazohine receptors and agmatinein blood vessels: A novel system
inhibiting vascular smooth mus-cle proliferation, 1272
Reid, I. A., see Chiu, N., 1073Reid, M. S., Hsu, K., Tolliver, B. K., Craw-
ford, C. A. and Berger, S. P.: Ev-idence for the involvement ofphosphohipase A2 mechanisms inthe development of stimulantsensitization, 1244
Reis, D. J., see Regunathan, S., 1272Reisine, T., see Liapakis, G., 1089
Remacemide
des-glycine metabohite, NMDA receptor
blockade by, 161NMDA receptor blockade by, 161
Renal tubulesdistal, cellular ATP depletion by iodoac-
etate and cyanide, 194proximal, calcium homeostasis in, lipid
A effects on, 555Rengasamy, A. and Johns, R. A.: Determi-
nation of Kmfor oxygen of nitric
oxide synthase isoforms, 30
Renin, secretion, stimulation by phos-
phodiesterase IV inhibitor rolip-
ram, 1073Repenfusion injury, myocardial, activated
protein C effects on infarct size,canine model, 1104
Reverse transcriptase, inhibitor UC 38,anti-HIV effects, 298
Rhoden, K. J., Tahhini, G. and Douglas, J.
S.: H�-K� ATPase inhibitors
cause relaxation of guinea pig
and human airway smooth mus-
cle in vitro, 897Richard, J., see Lew, R., 855Richards, J. B., see Sabol, K. E., 846
Rilmenidine, cardiovascular effects, imi-dazoline receptor interactions, inrabbits, 411
Ring, B. J., Cathow, J., Lindsay, T. J.,Gillespie, T., Roskos, L. K., Cer-
imehe, B. J., Swanson, S. P., Ham-mon, M. A. and Wrighton, S. A.:
Identification of the human cyto-
chromes P450 responsible for the
in vitro formation ofthe major ox-
idative metabohites of the anti-psychotic agent olanzapine, 658
Ritanserin, antipunishment effects, in pi-
geon, 388Rivier, J., see Liapakis, G., 1089Rivier, J., see Rodriguez de Fonseca, F., 56
Rodan, G. A., see Balena, R., 277Rodriguez de Fonseca, F., Rubio, P., Men-
zaghi, F., Merlo-Pich, E., Rivier,J., Koob, G. F. and Navarro, M.:Corticotropin-releasing factor
(CRF) antagonist[D-Phe12,Nle2�38,C”MeLeu37]CRF
attenuates the acute actions of
the highly potent cannabinoid re-ceptor agonist HU-210 on defen-sive-withdrawal behavior in rats,56
Rogawski, M. A., see Hough, C. J., 143Rogawski, M. A. , see Subramaniam, S.,
161Rogers, W. L., see Seymour, A. A., 708Rokach, J., see Powell, W. S., 728Rohipram, phosphodiesterase IV inhibitor,
stimulation of renin secretion,
1073
Roll, K., see Ujhehyi, M. R., 683
Roman, F., see Bouchard, P., 223Rosebrough, S. F. and Hashmi, M.: Galac-
tose-modified streptavidin-GC4antifibrin monoclonal antibodyconjugates: Application for two-step thrombus/embohus imaging,
770Rosen, M. I., McMahon, T. J., Hameedi, F.
A., Pearsahh, H. R., Woods, S. W.,Kreek, M. J. and Kosten, T. R.:Effect of chonidine pretreatment
on naloxone-precipitated opiate
withdrawal, 1128Rosenzweig-Lipson, S., see Bergman, J.,
942
Roskos, L. K., see Ring, B. J., 658Rossoni, G., Sala, A., Berti, F., Testa, T.,
Buccelhati, C., Molta, C., Muller-Peddinghaus, R., Maclouf, J. andFohco, G. C.: Myocardial protec-tion by the heukotriene synthesisinhibitor BAY X1005: Importance
1316 Index Vol. 276
of transcellular biosynthesis of
cysteinyl-leukotrienes, 335
Roxindole, psychopharmacological profile,41
Ruan, Y., see Kan, H., 934
Rubin, C. S., see Widnell, K. L., 306
Rubio, P., see Rodriguez de Fonseca, F., 56Rudolf, G. D., see Standaert, D. G., 342Ruffolo, R. R., Jr., see Bril, A., 637
Rusckowski, M., see Hnatowich, D. J., 326Russeh, F. G. M., see An, E. M. van der, 219
Russell, D. S., see Widnell, K. L., 306Russell, J. D., see McMahon, J. B., 298Rutaecarpine, vasorehaxing action, vascu-
lar smooth muscle and endothe-
hal cell calcium concentration,
1016Sabol, K. E., Low, R., Richards, J. B., Vos-
men, G.L. and Seiden, L. S.: Meth-
ylenedioxymethamphetamine-
induced serotonin deficits are
followed by partial recovery overa 52-week period. Part 1: Synap-tosomal uptake and tissue con-
centrations, 846
Sabol, K. E., see Low, R., 855Sacaan, A. I., Menzaghi, F., Dunlop, J. L.,
Correa, L. D., Whelan, K. T. andLloyd, G. K.: Epibatidine: A nico-tinic acetylchohine receptor ago-nist releases monoaminergic neu-
rotransmitters: In vitro and in
vivo evidence in rats, 509
Sadowski, B., see Mogil, J. S., 532Sagan, S., Chassaing, G., Praidier, L. and
Lavielle, S.: Tachykinin peptidesaffect differently the second mes-senger pathways after binding to
CHO-expressed human NK-1 re-ceptors, 1039
Sagratella, S., see Capasso, A., 743
Saita, K., Ohi, T., Hanaoka, Y., Furukawa,S., Furukawa, Y., Hayashi, K.and Matsukura, S.: A catechol de-
rivative (4-methylcatechol) acceh-
erates the recovery from experi-
mental acrylamide-induced
neuropathy, 231Saito, H., see Ohtomo, T., 1143Sakai, K., Nakahata, N. , Ono, H.,
Yamamoto, T. and Ohizumi, Y.:Homologous desensitization ofthromboxane A2 receptor ini32iNi human astrocytoma
cells, 829Sakakibara, F., see Hotta, N., 49Sakamoto, N., see Hotta, N., 49Sakamoto, S. , see Shimizu-Sasamata, M.,
84
Sakiyama, H., see Matsuyama, S., 989
Saha, A., see Rossoni, G., 335Samii, K., see Mazoit, J. X., 109Sanguinetti, M. C., see Sudo, G. Z., 951
Sannajust, F., see Chan, C. K. S., 41iSano, T., see Hnatowich, D. J., 326Sarwinski, S., see Lee, T. J.-F., 353SB 217242, pharmacological characteriza-
tion, 609
SCH 58261, pharmacological profile, 398Schecter, R. L., see Wang, T., 1169Schlicker, E., see Leurs, R., 1009Schmid, L., Bottlaender, M., Brouillet, D.,
Fuseau, C. and Maziere, M. : Vi-
gabatnin modulates benzodiaz-epine receptor activity in vitro: A
positron emission tomographystudy in baboon, 977
Schultz, R. J., see McMahon, J. B., 298Schupsky, J. J., see Raffa, R. B., 647Schur, M., see Ujhelyi, M. R., 683Schwinger, R. H. G., M#{252}hler-Ehmsen, J.,
BOhm, M. and Erdmann, E.: En-antioselective inotropic actions ofthe Nat-channel activators BDF9i48, BDF 9196 and BDF 9167 inhuman failing and nonfaihingmyocardium, 1180
Seedor, J. G., see Balena, R., 277Seiden, L. S., see Low, R., 855Seiden, L. S., see Sabol, K. E., 846Seizures, modulation by metabotropic glu-
tamate receptor ligands, in mice,516
Seki, J., see Kita, Y., 421Sekioka, K, see Abe, Y., 433Self, D. W., see Widnell, K L., 306Sensitivity, morphine, nociceptive assay
and, in genetic models, 532Sensitization, cocaine, K-opioid agonist ef-
fects on, 545Serotonin, see 5-Hydroxytryptamine
Serum proteins, bupivacaine binding, hu-man, 109
Settembrini, B. P., see De Gennaro Col-onna, V., 795
Severs, W. B., see Thompson, T. A., 1201Seymour, A. A., Asaad, M. M., Abboa-
Offei, B. E., Smith, P. L., Rogers,W. L. and Dorso, C. R.: Determi-nants of in vivo activity of neutralendopeptidase 3.4.24.11 and an-giotensin converting enzyme in-hibitors, 708
Shader, R. I., see von Moltke, L. L., 370Shahinfar, S., see Hatch, M., 187
Sham, W., see Davis-Cox, M. I., 758Shan, J., see Wang, G.-J., 1016Shen, D. D., see Adkison, K. D. K., 1189Shetty, S. S., see Chin, M. H., 74
Shimizu-Sasamata, M., Kawasaki-Yat-sugi, S., Okada, M., Sakamoto, S.,
Yatsugi, S.-I., Togami, J., Ha-tanaka, K-I., Ohmoni, J., Ko-shiya, K., Usuda, S. and Murase,
K. : YM9OK: Pharmacologicalcharacterization as a selectiveand potent a-amino-3-hydroxy-5-methyhisoxazole-4-propionate/kainate receptor antagonist, 84
Shiosaki, K., Jenner, P., Asin, K. E., Brit-ton, D. R. , Lin, C. W.,Michaelides, M., Smith, L., Bian-chi, B., Didomenico, S., Hodges,L., Hong, Y., Mahan, L., Mikusa,J., Miller, T., Nikkel, A., Stashko,M., Witte, D. and Williams, M.:ABT-431: The diacetyl prodrug of
A-86929, a potent and selectivedopamine D1 receptor agonist: Invitro characterization and effectsin animal models of Parkinson’sdisease, 150
Shippenberg, T. S., LeFevour, A. and Hei-dbreder, Ch.: K-Opioid receptoragonists prevent sensitization tothe conditioned rewarding effectsof cocaine, 545
Shoemaker, R. H., see McMahon, J. B., 298Sidhu, J. S. and Omiecinski, C. J.: Forsko-
lin-mediated induction of
CYP3A1 mRNA expression in pri-many rat hepatocytes is indepen-dent of elevated intracellular cy-chic AMP, 238
Sigma receptors, in vivo labeling, modula-tion by NPY and CGRP, in mouse
brain, 223Sills, M. A., see Chin, M. H., 74Simms, D. and Gallagher, J. P.: Modifica-
tion of serotonin responses in rat
dorsolaterah septal nucleus neu-
rons by acute and chronic cocaine,1292
Simon, R. P., see Graham, S. H., 1
Simpson, P. J., see Hahn, R. A., 1104Sleep, non-REM b, MK-801 effects on, 737Smit, H., see Mosehey, R. H., 561Smith, C. L., see Hnatowich, D. J., 326Smith, D. J., see Monroe, P. J., 65Smith, D. L., see Monroe, P. J., 65Smith, L., see Shiosaki, K., 150Smith, P., see Obistein, E. H., 609
Smith, P. L., see Seymour, A. A., 708Smooth muscle
airway, relaxation, H�-K� ATPase in-
hibitors and, guinea pig, 897colonic, relaxation by somatostatin, in
rabbit, 714
tracheal, chloride current, acetylcho-line-induced oscillations, in swinecells, 178
vascularcalcium dependence of indohactam-
mediated contractions, 867
imidazohine receptors and agmatinein blood vessels, 1272
Smooth muscle cells, vascularcAMP in, estradioh effects on, in rat
lung, 652
intracellular calcium concentration, ru-taecarpine effects, 1016
Sodium channel activators, enantioselec-tive inotropic actions of, humanmyocardium, 1180
Somatostatincolon relaxation by, in rabbit, 714effects on membrane potential and input
resistance of ventral subicularneurons, in rat, 426
stimulation, canine stomach, pentagas-
tric-stimuhated histamine releaseand, 984
Somatostatin receptors, subtype SSTR1,
development of a selective ago-nist, 1089
Song, J., see Miriel, V., 867Sorrentino, L., see Capasso, A., 743Spealman, R. D., see Bergman, J., 942Spodoptera frugiperda, D2 dopamine re-
ceptor coupling in, 784SSTR1, somatostatin receptor subtype, de-
vehopment of a selective agonist,1089
Stack, E. J., see Edwards, R. M., 125Standaert, D. G., Testa, C. M., Rudolf, G.
D. and Hohhingsworth, Z. R.: Inhi-bition of N-methyl-D-aspartateglutamate receptor subunit ex-pression by antisense ohigonucle-otides reveals their role in stria-tal motor regulation, 342
Stanulis, E. D., see Jeong, T. C., 1257Stark, C., see Bahena, R., 277Staruch, M. J., see Dumont, F. J., 1078Stashko, N., see Shiosaki, K., iSO
1996 Index 1317
Steir, C. T., Jr., see Fan, N. Y.-T., 875
Steroids, transport, organic anion trans-
porter of mammalian liver, 891
Stevens, C. W. : Relative analgesic potency
of mu, delta and kappa opioids
after spinal administration in
amphibians, 440
Stewart, J., see Ujhelyi, M. R., 683
Stinson, S. F., see McMahon, J. B., 298
Stitzer, M. L., see Eissenberg, T., 449
Streptavidin-GC4 antifibnin monoclonalantibody conjugates, galactose-
modified, two-step thrombus/
embolus imaging application, 770
Striatum
dopamine D1 receptor effects, receptordesensitization, studies with
A-77636, 1022
GABA receptors, effects of repeated co-
caine injections, 1002Subiculum, ventral neurons, somatostatin
effects on membrane potential
and input resistance, in rat, 426
Subramaniam, S. , Donevan, S. D., and Ro-gawski, M. A.: Block of the N-methyl-D-aspartate receptor by
remacemide and its des-glycinemetabohite, 161
Substance P, human NK-i receptors,
tachykinin peptide effects, CHO
cells, 1039
Sudo, G. Z. and Sanguinetti, M. C.: Intra-
cellular [Mg� ‘idetermines speci-ficity of K� channel block by aclass III antiarrhythmic drug,
951Sugihara, H., see Yamada, K., 460Sulfation, total parenteral nutrition ef-
fects on, in rats, 602
Sulfhydryls, direct cellular protection by,
gastric mucosal cells, ii74
Sullivan, J. P., see Gopalakrishnan, M.,289
Sun, F. F., see Taylor, B. M., 1224Sun, F. F., see Yue, G., 265Swanson, S. P., see Ring, B. J., 658Synaptosomes
dopamine release, presynaptic controlby cholinergic and NMDA recep-
tons, in rat striatum, 616
MDMA-induced serotonin deficit up-take, 846
Syncytiah microvillus membrane vesicles,
cimetidine uptake into, in humanterm placenta, 219
Szabo, S., see Glavin, G. B., 1174Szarowski, D., see Davis-Cox, M. I., 758Sze, P. Y.: Glucocorticoid interactions with
ethanol effects on synaptic
plasma membranes: Influence on
[1251]calmoduhin binding, 578
T2, IL-2 transcription suppression by, 316Tachykinin peptides, modulation of hu-
man NK-i receptors, CHO cells,
1039
Tachykinins, intrathecal, effects on elec-
trocorticographic desynchroniza-tion, in rats, 212
Tachyphylaxis, to angiotensin II, in rat
mesenteny in vivo, 13Tacrine, see Tetrahydro-9-aminoacridineTakamatsu, H., see Kita, Y., 421Tahlini, G., see Rhoden, K J., 897Tanaka, C., see Matsuyama, S., 989
Tao, X., Davis, L. S., Hashimoto, K. andLipsky, P. E.: The Chinese herbal
remedy, T2, inhibits mitogen-induced cytokine gene transcrip-tion by T cells, but not initial sig-
nal transduction, 316
Tassaneeyakul, W., Birkett, D. J., Ed-
wards, J. W., Veronese, M. E.,Tassaneeyakul, W., Tukey, R. H.and Miners, J. 0. : Human cyto-chrome P450 isoform specificityin the regiosehective metabolism
of toluene and o-, m- and p-xyhene, 101
Tassaneeyakul, W. , see Tassaneeyakul,
W., 101Taurine, saturable cerebrospinal fluid dis-
position, in rat, 676
Taylor, B. M., Fleming, W. E., Benjamin,C. W., Wu, Y., Mathews, W. R.and Sun, F. F. : The mechanism of
cytoprotective action of lazaroids
I: Inhibition of reactive oxygenspecies formation and lethal cell
injury during periods of energydepletion, 1224
Technetium-99m, -labeled phosphodiesterDNA vs phosphorothioate DNA,
in vitro and in mice, 326
Teraoka, K., see Morita, K., 996Tesson, F., Limon, I., Gargahidis-Mouda-
nos, C. and Parini, A. : I2-Imidazo-
line binding sites: Relationship
with different monoamine oxi-dase domains and identification
ofhistidine residues mediating li-
gand binding regulation by W’,
359Testa, C. M., see Standaert, D. G., 342Testa, T., see Rossoni, G., 335Tetrahydro-9-aminoacridine, effects on
muscarinic and opioid currents,in rat locus ceruleus neurons, 137
Tetrodotoxin, effects on 5-HT1D receptors,in rat midbrain raphe nuclei, 697
Theophylhine, metabolism, human liver
microsomes, 912
Thom, S. R., see Chen, Q., 929Thompson, T. A., Lewis, J. B., Dejneka, N.
S. , Severs, W. B., Polavarapu, R.
and Bilhingsley, M. L.: Induction
of apoptosis by organotin com-
pounds in vitro: Neuronal protec-
tion with antisense ohigonucleo-
tides directed against stannin,
1201
Thompson, W. J., see Haynes, J., Jr., 752Thomsen, C., see Dalby, N. 0., 516
Thornton-Manning, J., Appleton, M. L.,Gonzalez, F. J. and Yost, G. S.:Metabolism of 3-methylindole byvaccinia-expressed P450 en-
zymes: Correlation of 3-methyl-eneindolenine formation and pro-
tein-binding, 21
Thrombosis, factor Xa, DX 9065A inhibi-
tion of, 1030Thromboxane A2 receptors, desensitiza-
tion, in i321N human astrocy-
toma cells, 829Thrombus/embolus imaging, two-step, ga-
lactose-modified streptavidin-
GC4 MAb conjugates for, 770
Timmenman, H., see Leurs, R. , 1009
Tirilazad mesylates, 21-aminosteroid, IBDamelioration by, in rats, 265
Tjia, J. F., Colbert, J. and Back, D. J.:
Theophylhine metabolism in hu-
man liver microsomes: Inhibition
studies, 912
TKS159, effects on gastric motility and
acetyhchohine release, guinea pigstomach, 989
T lymphocytes
activation, and CB1 cannabinoid recep-
tors, 776
IL-2 transcription, suppression by T2,
316Tofovic, S. P. and Jackson, E. K.: Tachy-
phyhaxis to angiotensin II and[Phe4]-angiotensin II in the rat
mesentery in vivo, 13
Togami, J., see Shimizu-Sasamata, M., 84
Tokarz, J. J., see Lash, L. H., 194
Tolerance, see also Dependencechronic ethanol, reversal by cAMP-
dependent protein kinase, 365Tolliver, B. K., see Reid, M. S., 1244Tohuene, cytochrome P450 isoform metab-
ohism, human, 101
Torphy, T. J., see Manning, C. D., 810
Total parenteral nutrition, effects on he-
patic drug conjugation, in rats,
602Tracheal smooth muscle
chloride current, acetylcholine-inducedoscillations, in swine cells, 178
H�-K� ATPase inhibitors and, humanand guinea pig, 897
Traylor, L. A., see Proksch, J. W., 555Triazoham, biotransformation by liver mi-
crosomes in vitro, human, 370
Tributylmethyhammonium, hepatic up-
take and bihiary excretion, ratliver plasma membrane vesiclestudies, 561
Tributyltin, selective toxicity of, induction
of apoptosis by organotin com-
pounds, 1201
Triethyltin, selective toxicity of, induction
of apoptosis by organotin corn-
pounds, i2Oi
TrifunoviC, R. D. and Brodie, M. S.: Theeffects ofchomipramine on the ex-
citatory action of ethanol on do-paminergic neurons ofthe ventraltegmental area in vitro, 34
Trimethyltin, selective toxicity of, induc-
tion of apoptosis by organotin
compounds, 1201
Tripterygium wilfordii Hook F, T2 extract,
suppression of IL-2 transcription
by, 316
Trizna, W., see Edwards, R. M., 125Tukey, R. H., see Tassaneeyakul, W., 101
Tumor necrosis factor, production, modu-
lation by methylxanthines and,
mouse liver, 968
Turner, J. N., see Davis-Cox, M. I., 758
UC 38, anti-HP! effects, 298U74006F, IBD amelioration by, in rats,
265US0,488H, antinociception induced by,
cromakahirn effects, 1136
Ujhelyi, M. R., Bottorif, M. B., Schur, M.,
Roll, K., Zhang, H., Stewart, J.,
and Markel, M. L.: Urine acidifi-
cation affects the activity of the
1318 Index Vol. 276
organic base transporter in a non-
stereoselective manner, 683
Uratehomeostasis, hosartan effects on, 187
transport
intestinal, losartan effects on, 187
renal brush-border membrane, All
antagonist interactions, in rat,
125
Urine, acidification, enhancement of or-
ganic cation secretion by, 683
Usuda, S., see Shimizu-Sasamata, M., 84
Vagus stimulation, E-4031 effects on, in
dogs, 467
Vaidya, V. A., see Widnell, K. L., 306
Valproic acid, uptake, rat brain, medium-
chain fatty acid transporter medi-
ation of, ii89
VanBoom, J. H. , see Ouwerkerk-Ma-hadevan, S., 923
Van Solkema, B. G. H., see Moseley, R. H.,
561Vargas, R., see Farhat, M. Y., 652
Varma, D. R., see Deng, X. F., 1155
Vascular smooth muscle cells, cAMP in,
estradiol effects on, in rat hung,
652Vasoactive intestinal peptide, effects on
K� channels, mediation by G pro-tein, 690
Vasoconstriction, hypoxic pulmonary, re-
versal by EHNA, in rat hung, 752
Vasodilation, cerebral neurogenic, inhibi-
tion by L-glutamine and NOS, 353
Vasopressin, antidiuretic response to lan-
reotide and, diabetic rat, 875Vaziri, N. D., see Hatch, M., 187Ventral tegmental area, dopaminergic
neurons, ethanol-induced excite-
tion of, effects of clomipramine
on, in vitro, 34
Ventricular arrhythmia, BRL-32872 anti-
arrhythmic profile, 637
Ventricular myocytes
potassium channel block by class II an-
tiarrhythmic drug, intracellular
magnesium effects, 951subtypes of muscarinic receptors in,
prostacychin synthesis, rabbit
heart, 934
Veronese, M. E. , see Tassaneeyakuh, W.,
101
Verrijt, C. E. H., see Aa, E. M. van der, 219Vertebrae, L5, histomorphometric analy-
sis, with long-term alendronate,in adult dogs, 277
Vigabatrin, modulation of benzodiazepinereceptor activity, positron emis-
sion tomography study, baboon,
977
Vignon, J., see Prinssen, E. P. M., 904
VIP, see Vasoactive intestinal peptide
Vistica, D. T., see McMahon, J. B., 298
Vollinga, R. C., see Leurs, R., 1009
Von Geldern, T. W., see Opgenorth, T. J.,
473
von Moltke, L. L., Greenbhatt, D. J., Har-
matz, J. S., Duan, S. X., Harrel, L.
M., Cotreau-Bibbo, M. M., Prit-
chard, G. A., Wright, C. E. and
Shader, R. I.: Triazolam biotrans-
formation by human liver micro-
somes in vitro: Effects of meta-
bohic inhibitors and clinical
confirmation of a predicted inter-
action with ketoconazole, 370Vosmer, G. L., see Lew, R., 855Vosmer, G.L., see Sabol, K. E., 846
Wainscott, D. B., Kursar, J. D., Baez, M.
and Nelson, D. L. : Pharmacologic
characterization of the human
5-hydroxytryptamine25 receptor:Evidence for species differences,
720
Wakao, T., see Hotta, N., 49
Wang, G.-J., Shan, J., Pang, P. K. T.,
Yang, M. C. M., Chou, C.-J. andChen, C-F. : The vasorelaxing ac-tion of rutaecarpine: Direct para-
doxical effects on intracellularcalcium concentration of vascularsmooth muscle and endothehial
cells, 1016
Wang, H., see Regunathan, S., 1272
Wang, S., see King, B. F., 93Wang, T., Chen, X., Schecter, R. L., Ba-
rucheh, S., Ahaoui-Jamahi, M.,
Melnychuk, D. and Batist, G.:Modulation of glutathione by acysteine pro-drug enhances in
vivo tumor response, 1169
Wang, W., see Moseley, R. H., 561
Wang, Y.-H., see Munir, M., 819Weinstock, J., see Edwards, R. M., 125Wendel, A., see Leist, M., 968Wessale, J. L., see Opgenorth, T. J., 473Whelan, K T., see Sacaan, A. I., 509Whigan, D. B., see Grover, G. J., 380Widnell, K. L., Self, D. W., Lane, S. B.,
Russell, D. S., Vaidya, V. A.,Miserendino, M. J. D., Rubin, C.S., Duman, R. S. and Nestler, E.J.: Regulation of CREB expres-sion: In vivo evidence for a func-tional role in morphine action in
the nucleus accumbens, 306Wiederrecht, G., see Dumont, F. J., 1078Willer, J.-C., see Bustamante, D., 1232
Williams, M., see Shiosaki, K., 150
Williams, S. A., see Abbruscato, T. J., 1049
Willis, W. D., see Lin, Q., 958
Willis, W. D., see Peng, Y. B., 116Winn, M., see Opgenorth, T. J., 473Winnard, P., Jr., see Hnatowich, D. J., 326Winsauer, P. J., Bixler, M. A. and Mehe, P.
C.: Comparison of the effects oftypical and atypical anxiolytics
on learning in monkeys and rats,
liii
Withdrawalacute HU-2i0 effects on, mediation by
corticotropin-releasing factor, in
rats, 56
acute opioid, dexamethasone effects on,743
buprenorphine, antagonist-precipitated,
in humans, 449
Witte, D., see Shiosaki, K., 150
Wolfe, B. B., see Mumr, M., 819Wong, P. Y.-K., see Yue, G., 265Woods, E. B., see Lash, L. H., 194
Woods, S. W., see Rosen, M. I., 1128Wouterse, A. C., see An, E. M. van der, 219
WRC-057i, characterization, 490Wright, C. E., see von Moltke, L. L., 370
Wrighton, S. A., see Ring, B. J., 658
Wu, D., Boado, R. J. and Pardridge, W. M.:Pharmacokinetics and blood-brain barrier transport of [3H]-
biotinylated phosphorothioate oh-
godeoxynucheotide conjugated toa vector-mediated drug deliverysystem, 206
Wu, P. H., Liu, J.-F., Wu, W. L., Lan#{231}a,A.J. and Kalant, H.: Development ofalcohol tolerance in the rat after a
single exposure to combined
treatment with arginine8-vaso-
pressin and ethanol, 1283
Wu, W. L., see Wu, P. H., 1283
Wu. Y., see Taylor, B. M., 1224
Wu-Wong, J. R., see Opgenorth, T. J., 473WY 50,324, antipunishment effects, in pi-
geon, 388
Wysocki, R. J., Jr., see Martin, P. L., 490
Xenopus laevis, follicular oocyte P1 purino-ceptors, 93
Xie, Y., McHugh, T., McKay, J., Jones, G.S., Jr. and Loring, R. H.: Evidence
that a nereistoxin metabolite, and
not nereistoxin itself, reduces
neuronal nicotinic receptors:Studies in the whole chick cihiary
ganghion, on isolated neurons andimmunoprecipitated receptors,169
Xing, P. L., see Glavin, G. B., 1174
Xu, J., see Pnimus, R. J., 882Xyhene, cytochrome P450 isoform metabo-
hism, human, 101
Yamada, K, see Ahi, H., 837Yamada, K., Noda, Y., Hasegawa, T.,
Komori, Y., Nikai, T., Sugihara,H. and Nabeshima, T.: The role ofnitric oxide in dizocilpine-induced
impairment of spontaneous alter-nation behavior in mice, 460
Yamamoto, T., see Sakai, K., 829
Yang, M. C. M., see Wang, G.-J., i016Yang, X., Criswell, H. E. and Breese, G. R.:
Nicotine-induced inhibition inmedial septum involves activa-
tion of presynaptic nicotinic cho-
hinergic receptors on y-aminobu-tynic acid-containing neurons,
482Yasuhara, M., see Ohtomo, T., 1143Yatsugi, S-I., see Shimizu-Sasamata, M.,
84
Yin, K., see Yue, G., 265YM9OK, pharmacological characteniza-
tion, 84
Yoo, S. D., Holladay, J. W., Fincher, T. K.,Baumann, H. and Dewey, M. J.:Altered disposition and antide-
pressant activity of imipraminein transgenic mice with elevated
alpha-i-acid glycoprotein, 918Yost, G. S., see Thornton-Manning, J., 21Young, R. and Glennon, R. A.: A three-
layer operant procedure differen-
tiates the stimulus effects of R(-)-MDA from S(+)-MDA, 594
Youngson, C., see Regunathan, S., 1272
Yu, J., see Primus, R. J., 882
Yue, G., Sun, F. F., Dunn, C., Yin, K andWong, P. Y.-K.: The 2i-aminos-teroid tirihazad mesylate canameliorate inflammatory bowel
disease in rats, 265
Zack, J. A., see Pardridge, W. M., 246Zamir, N., see Porat, 0., 1162
1996 Index 1319
Zamir, 0., see Porat, 0., 1162Zhang, H., see Ujhelyi, M. R., 683Ziganshin, A. U., see King, B. F., 93Ziganshina, L. E., see King, B. F., 93Zocchi, C., Ongini, E., Conti, A., Monopohi,
A., Negretti, A., Baraldi, P. G.
and Dionisotti, S.: The non-xan-thine heterocychic compound SCH58261 is a new potent and sehec-tive A2,, adenosine receptor an-tagonist, 398
Zohi, M., see De Gennano Colonna, V., 795Zou, H., see Mirieh, V., 867
.
I
;�‘:4, �
:td� � )iTS (i�
� �an contact Iqaku-S�o)c!dbe’ 31 19%
,‘.,,�1o
, . y � I � “
1�pany I
Williams & WilkinsA WAVERLY COMPANY
.- --- . � �----- -- I
���jIj I �i�I
I__ . � . r,ION
publishes experimetit�ir . �vit’ro andm t)j(70 systems that F�±� �gnificant and
original information on � .iolisrn and disposi-
tiOn of endogenous and exo� �us compounds, in-
cluding the metabolism of th �eutic agents and
environmental chemicals. The journal also iiwites
timely reviews, short communications and letters to
the Editor. All submissions are refereed to en�ore a
high standard of publication. The areas covered are:
. metabolism, metabolite identification and
mechanisms of metabolite formation
expression of drug metabolizing enzymes
regulation of drug metabolizing enzyme
gene expression
. toxicological consequences of xenobiotic
metabolism
. pharmacokinetics
I pl�i�nacodynamics
T his’�umal should be a standard reference in all
pharmacology and toxicology departments. It is
also a valuable resource for all medicinal chemists
invol�’ed in drug design and all hiochernists with
interest in dfllg metabolism, expression or drug
metabolizing enzymes and regulation of drug
metaholi:ing en:yme gene expression. Monthly
To order hy credit card, call TOLL-FREE
1 -800-638-642 3 in North America. Outside
North Americi, t�ix: 1-4 1 i.)- 36 l-8C�48 or call one
of our intern�itionaI othees: Tokyo (03) �689-54OO,
.� � I.()I’ILIOIl C�I 7 1- 3��-2�57. Flong Kong ?�52-2#{244}l0-2 3 39.
1. � .
� .$�
r�tl�Iv)
�� �
�j
S) -
�:
�p date .#{149}
�!�
COPYRIGHT © 1996 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
MO
PHARUEditor: Raymond Dingledine, Ph.D.
Emory University School of Medicine
Atlanta, Georgia
Is your special interest receptors and
neurotransmitters...drug metabolism. ..antibic
and anticancer drug actions...or other areas
related to molecular basis of drug action? If �you should be subscribing to MOLECULAI
PHARMACOLOGY.
The editor’s and editorial board’s high
standards ensure that the papers you read in
MOLECULAR PHARMACOLOGY are on
the cutting edge of research on drug action and
selective toxicity at the molecular level.
Original applications of biochemistry,
biophysics, genetics, and molecular biology are
juxtaposed with innovative pharmacologic
research to elucidate basic problems inpharmacology and toxicology, including such
areas as molecular mechanisms involved in
drug receptor-effector coupling, xenobiotic
metabolism, and antibiotic and anti-cancer drug
action. Start your subscription today to ensure
access to the most newsworthy papers in your
field. Monthly
Cut out and send in the coupon or call
to start your subscription immediately,
1-800-638-6423 from anywhere in North
America. Outside North America, fax 1-410-
361-8048 or call one of our international
offices: Tokyo (03) 5689-5400, London 017 1-
385-2357, Hong Kong 852-2610-2339.
Williams & WilkinsA WAVERLY COMPANY
( YES! Enter my subscription.
�*... Avoid future rate increases and ensure uninterrupted
I service-enter your multiyear subscription today!
I MOLECULAR PHARMACOLOGY(monthly) I
� Individual: $1 15/yr Institution: $250/yr
I (Please add $35.00/yr. outside the U.S.; in Canada. also add 7% GST.)
I New Subscription Renewal II 3yrs 2yrs lyr I
I Name � � �----. �-�-----�-�--- --- - �- �- I
� Address �______________________________ -�- -- � -------�
I City/State/Zip ________--------� - II Payment Options: II Check enclosed (payable to Williams & Wilkins) II Bill me American Express II MasterCard VISA I
I Card # �- Exp. date II Signature or P.O. # ____________________ I
MD. ME. and IL subscnber�, must add state �aIes tax. Subscriptions outside the t1.S. rnu�t beprepaid in U.S. dollar’.. International order’.. fax xour order to -410-361-8048. In Japan.contact gaku.Shoin. MYW. Ltd. (03) �f�59.J4(5�j Rates valid through October 31. 996.
Dixcounts available to members on all ASPET puhlicationx. SAVE lO� when ordcrin� two.
I SAVE l5� when ordering three. SAVE 2O� when ordering all four puhltcations. II Williams & Wilkins II i�is. A Waverly Company II P.O. Box 23291
I Baltimore. MD 21203-9990
�M��±S PrIrnCdrnUSAS#{212}JO3OZJ
���ggy Jou rnalsPubilcatlons of the American Soclety for Pharmacology and Experlmental Therapeutics, Inc.
r
Return coupon to:Williams & Wilkins
A WAVERLY COMPANY
P.O. Box 23291. Baltimore. MD 2l203-999()I Pharmacological Reviews (quaiierI� I
I �1 Iit&li do ii S( i/x it �1 In tituti n ii S I I -i/x ir 1 In tr itnttt�. ‘S0/x ar I Add � � r dit .trd rd r all TOLL tREE I 50(1 615 64 � in \ )rth Amt.rw i
I 520/year for xuhscrtptioiix otttxide the [.S.: in Cattada. tl�.() .111(1 7� CJST. I Outside North America, fax 1-410-361-8048 or call one ot our international
I � Nc�� Subscription �1 Rciicx� :iI . offices: Tokyo (03) �$9.449) Londin Ol71.3$�2357, Hong Kong M�2.26l(I.2339Suh.crits, for: �1 3 �earx �1 2 �carx �1 I scar . S6J(O�/
[Jf�h4u
The Journal of Pharmacology and Experimental
Therapeutics
Editor: John A. Harvey. Ph.D.
JPET is respected the world over as one of the
leading research journals in the field of pharmacology. You’ll
find broad coverage of all aspects of the interactions of
chemicals with biological systems. including autonomic.
behavioral. cardiovascular. cellular. clinical. developmental.
gastrointestinal. in�iiiuno-. neuro-. pulmonary. and renal
phariiiacology. as well as analgesics. drug abuse. metabolism
atid disposition. cheniotherapy. and toxicology. i%’loiit/ilv.
Molecular Pharmacology
Editor: Raymond Dingledine. Ph.D.
The papers published in Molecular Pharmacology
are on the cutting edge of research on drug action and selective
toxicity at the molecular level. Original applications of
biochemistry. biophysics. genetics. and molecular biology are
juxtaposed with innovative pharmacologic research to elucidate
basic problems in pharmacology and toxicology. including such
areas as molecular mechanisms involved in drug receptor-
effector coupling. xenobiotic metabolism. and antibiotic and
anticancer drug action. Mouth/v
Drug Metabolism and Disposition: The Biological Fate
of Chemicals
Editor: Raymond F. Novak. Ph.D.
Drug Metabolism and Disposition publishes
experimental results from in vitlo and in t’ii’o systems that bring
VOL.1 signilicaiit and original information on metabolism and
disposition of endogenous and exogenous compounds. including
pharmacologic agelits and environmental chemicals. The areas
covered are: xenohiotic metabolism. expression of drug
metabolizing enzynies. regulation of drug metabolizing enzyme
gene expression. pharmacoki netics. pharmacodynamics and
toxicological consequences of xenohiotic nietabolism.
Mouth/v.
Pharmacological Reviews
Editor: David B. Bylund. Ph.D.
Pharmacological Reviews is a showcase forlniport�Lnt review articles in your field. featuring longer papers
Oil topics of high current interest. The areas covered in review
papers have included biochemical and cellular pharmacology.
drug nietaholisni and disposition. renal pharmacology.
neuropharmacology. hehav ioral pharmacology. clinical
pharmacology. and toxicology. No library serving the
pharmacologic community should he without a subscription.
Qiuiuu’u-/v.
� Plcaxc enter tt�t�. ..tth..crtpltttn E� the lolloo tog:
The journal of Pharmacology and ExperimentalI’herapeutics iit,t’,ttltlvj
-1 mdix idu�tl S I 90/sear 1 loxtitulional S370/�ear ( Add S75/vc�tr fur
suhxcrtpttuns ottt’.tde tic U.S. : to C’�tnada. �t1’.tt �tik1 7� GST.
I � Nc�� Suhx�rtptitttt 1 Rcneo alSuhxcrthe fur: -1 3 vcarx 1 2 yt.-arx 1 1 sear
I)rug \letaholism and I)isposition � ,,iu,tt/tlv
�1 lttijtx Ju�il S9O/� car �1 ltmttttittttnal S I 5O/�� car ( .\dJ 525/s car for suhxcrtpttons
t)LItxtdt.� the �: .s. : to (��ttt�tda. �tlMl add 7( � (ST.
�1 Ncx� Suhxcttptt(In �1 Rcncxx
Suhxcrthc t&tr: 1 3 scar-. �1 2 \carx 1 I scar
I Molecular Pharmacolog� I nuxitltlv I�1 ltkltx idu�tl S I I 5/� t�ar 1 Inxtilutiutial S250/� ear � Add S35/� car for
I suh-.crtpttonx outxtdc the IS.: in Canada. �tlx() add 7� (‘IST. I
�1 Neo Suhx�rtptton 1 Rcnexxal
Suh-..ribc for: �1 3 \earx 1 2 sears 1 I \ear
;:7
!�: �. � � � �.- -.
� � �(
3. �
�.
� .�;:..1.Ii
* � � r .� I
� �i;-4� �
. . I. . ‘l
., . .
:/ . .
,�.,- �:
�Payment Options: � 1 . .
1.Check encloied (payable to
Willi�mis&.Wilkins) . .
1.Bilt me �i A�iierican Express r � � � � � � �
iMasterCard 1VISA Card#
Exp. date Signature or P.O. #
Nanie
Addrcsx
City/State/Zip
�I Plea’.c indicate institution/’�tatus
\tt). II . .itt�l ��lL .uh..criber.. itu..t .idd tate ..ale� t.i�. Siih�� riptirt� ‘tit.,tlc the I S nut heprcpii�l in I S di’tt.it� In J.ip.in. �iiitt.tct lg.iktt-Shiiiii. \tt’iS. Ii,l I 1.1 i �(,iii).c4(Xi R.tc� ‘ �iti�lthritigh ( Ii. tiih�r .i I . I